Multi-objective Optimisation, Sensitivity and Robustness Analysis in FBA Modelling

Jole Costanza¹, Giovanni Carapezza¹, Claudio Angione², Pietro Liò², and Giuseppe Nicosia¹

¹Department of Mathematics and Computer Science, University of Catania ²Computer Laboratory, University of Cambridge {costanza,carapezza,nicosia}@dmi.unict.it {claudio.angione,pietro.lio}@cl.cam.ac.uk

Abstract. In this work, we propose a computational framework to design in silico robust bacteria able to overproduce multiple metabolites. To this end, we search the optimal genetic manipulations, in terms of knockout, which also guarantee the growth of the organism. We introduce a multi-objective optimisation algorithm, called Genetic Design through Multi-Objective (GDMO), and test it in several organisms to maximise the production of key intermediate metabolites such as succinate and acetate. We obtain a vast set of Pareto optimal solutions; each of them represents an organism strain. For each solution, we evaluate the fragility by calculating three robustness indexes and by exploring reactions and metabolite interactions. Finally, we perform the Sensitivity Analysis of the metabolic model, which finds the inputs with the highest influence on the outputs of the model. We show that our methodology provides effective vision of the achievable synthetic strain landscape and a powerful design pipeline.

Keywords: Cell Metabolism, Biological CAD, Sensitive and Fragile Pathways, Genetic Design, Multi-Objective optimisation, Flux balance analysis, Sensitivity and Robustness Analysis.

1 Introduction

Metabolic engineering is central in Biotechnology and has impact also in basic cellular biology. The aim of metabolic engineering is to direct specifically a flux through a metabolic pathway, for instance a product made during the fermentation. To this end, one needs a deep understanding not merely of the genetics of a microorganism, but also of its metabolic capacity (i.e. the amount of all the intermediates). Remarkably, through genetic manipulations (in terms of knockouts) carried out on bacteria, one can overproduce one or more metabolites of interest. A gene knockout is a genetic technique in which one gene in an organism is made inoperative through a base mutation or a deletion. Sometime the inactivation of one gene results in the inactivation of all the downstream genes of the operon. These manipulations are very useful for classical genetic studies

as well as for modern techniques including functional genomics. Recently, many organisms have been used to analyse their metabolite production potential and to identify the metabolic interventions to produce the metabolite of interest. Indeed, strains have been systematically designed in vivo to overproduce target metabolites such as lycopene [1], ethanol [2], isobutanol [3] and many others.

Metabolic engineering requires mathematical models for accurate metabolic reconstruction of strains, as well as for seeking non-native synthesis pathways. A recent research methodology, called Flux Balance Analysis (FBA) [4], studies biochemical networks, in particular the genome-scale metabolic network reconstructions. These network reconstructions contain all of the known metabolic reactions in an organism and the genes that encode each enzyme. FBA calculates the flow of metabolites through this metabolic network, thereby making it possible to predict the growth rate of an organism or the rate of production of a biotechnologically important metabolite at steady state. Being at steady state, FBA manages large networks very quickly, since it does not require kinetic parameters. This makes it well suited to research on perturbations and genetic manipulations (knockouts) that bacteria might undergo. One of the major advantages of performing computational analysis of stoichiometric models is that the pathways are system proprieties emerging under particular genetic background and nutritional conditions. In other words, the FBA provides better treatment of metabolism than classical biochemistry drawings of metabolic pathways.

By using computational metabolic engineering methods, it is possible to explore the reaction network and search for the genetic interventions to optimise the objectives. By making inoperative the genes, the enzymes that are normally synthesised by those genes are not present anymore in the biological system. In this way, also the corresponding biochemical reactions, normally catalysed by these enzymes, do not occur. Then, the chemical species that constitute the reagents and products of these reactions do not undergo the transformations. The aim is to find the genetic manipulations that change the metabolic process in an organism, in order to increase the flow of desired metabolites, chosen according to biotechnological purposes. Additionally, changing the natural genetic function in an organism may cause the death of the growth cell. Therefore, finding genetic manipulations is a hard problem of search and optimisation.

For all the above reasons and since designing gene knockout in laboratory is very expensive and time-consuming, in the past years a variety of methods has been implemented in order to predict in silico the best knockout strategies that optimise a cellular function of interest. These methods are based on evolutionary algorithms [5], simulated annealing [6], bi-level optimisation framework [7], and mixed-integer linear programming (MILP) [8,9]. All have been tested in FBA organism models, but they require high computational efforts, since the execution times grow exponentially [8,6,5] or linearly [7] as the number of manipulations allowed in the final designs increases. Moreover, cellular metabolism is composed of a large number of reactions, thus the dimension of the solution space is very large and finding genetic manipulations is computationally expensive.

In this work, we present a novel Multi-Objective optimisation algorithm denoted by Genetic Design through Multi-Objective (GDMO), in order to search for the genetic manipulations that optimise multiple cellular functions of interest. Our idea is to use the Pareto optimality to obtain not only a wide range of Pareto optimal solutions, but also the best trade-off design. In this context, the multiple biological functions are represented by desired productions, e.g., vitamins, proteins, biofuel, biomass formation, antibodies, electron productivity, or the energetic yield of the organism. For this application, a Pareto solution represents a strain with a particular genetic manipulation (genotype), and that is specialised to overproduce selected metabolites (phenotype), with respect to the wild type (i.e., a strain with genes that are all operative). We test our knockout-based multi-target optimisation on the most recent metabolic data concerning Escherichia coli, Geobacter [10], Methanosarcina barkeri [11], and *Yersinia pestis* [12]. We report that multi-objective optimisation provides more insights than single optimisation on the capability of these organisms to adapt to the simultaneous presence of different conditions and constraints. Furthermore, our method is able to explore effectively the whole space of knockouts. We tested the performance of GDMO by maximising acetate and succinate production rates, and other multiple biological functions in E. coli, iAF1260, and comparing it against previous methods.

GDMO is accompanied by a robustness analysis that performs the local, global robustness and the Normalised Feasible Parameter Volume of the genetic manipulation proposed by GDMO. For each strain, we compute the robustness indexes, in order to estimate how robust is a strain obtained by GDMO when it undergoes small perturbations, external (changes in the nutrients) or internal (changes in the metabolism). This way, we are able to choose the most robust strain proposed by GDMO. Finally, the Sensitivity Analysis investigates the species solution space and determines the influence of each specie on the output of the FBA model.

2 Methods

2.1 GDMO: Genetic Design through Multi-Objective Optimisation

GDMO is a combinatorial global search method that finds the genetic manipulation strategies to simultaneously optimise multiple cellular functions (i.e., objective functions) in metabolic networks modelled with Flux Balance Analysis (FBA) and Gene-Protein-Reaction (GPR) map. The simultaneous optimisation of multiple objectives differs from the single-objective optimisation because the solution is not unique when the objectives are in conflict with each other. In a maximisation problem objectives are in conflict when the increment of an objective, causes the decrement of at least another one.

The solution of a multi-objective problem is a potentially infinite set of points, called *non-dominated* solutions or *Pareto front*. In a maximisation problem, a solution is Pareto optimal if there exist no feasible solutions that increase some objective without causing a simultaneous decrease in at least one other objective.

In our problem, the genotype of a bacterium is mathematically represented by a string of bits $y \in \{0, 1\}^L$. Each bit in y is a gene set that distinguishes between single and multi-functional enzymes, isozymes, enzyme complexes and enzyme subunits; this way, it captures the complexity and diversity of the biological relationships through a Boolean approach. For example, when the genes of the l-th set are all necessary to catalyse the corresponding reactions (a single gene set can linked to more reactions), genes are related by "AND"; otherwise if it is necessary at least a gene, genes are linked by "OR". When the l-th element of y is set to 1, the corresponding gene set is inoperative. Therefore, y represents the vector of decision variables to be found, in order to obtain the higher values of objective functions, satisfying particular constraints (for instance a maximum number of gene knockouts allowable). A point y^* in the solution space is said to be Pareto optimal if there does not exist a point y such that F(y) dominates $F(y^*)$, where F is the vector of r objective functions. The variable space, (i.e., the domain of y) is defined in a discrete space.

The method we present implements a genetic algorithm inspired by NSGA-II [13] and is composed of 4 key steps. We start with the *initialisation* of the population *Pop* and the computation of the fitness score. The population *Pop* is a set of individuals, i.e., a set of feasible solutions. *Pop* is represented by a $I \times (L + r + 2)$ matrix, where I is the number of individuals, L is the number of the decision variables and r is the number of the objective functions, obtained solving the problem (2). The last two columns are used to store two parameters of the algorithm linked to each individual and useful to evaluate the quality of the solution. Each individual is composed of the proposed knockout strategy \tilde{y} and the corresponding objective function values. Each generation select the individuals that are maximal with respect to the product ordering. The individuals of the initial population can be initialised in different ways: either randomly, assigning present status to all genes or selecting a set of knocked out genes.

Successively, three steps are iteratively carried out. In a binary tournament selection process, two individuals are selected at random, and their fitness is compared. The individual with the best fitness is selected as a parent. The algorithm selects a number of parents (i.e. the best individuals) equal to the half of the population. Parents are mutated using a combinatorial mutation operator convenient to create an offspring population. Mutation represents a switch, from 0 to 1, or from 1 to 0 for the *l*-th gene set. The process is randomly executed and for each parent individual ten offspring have been formed and only the best is chosen. Mutation can achieve the maximum knockouts number equal to the parameter C (fixed to 50 by default). A novel population of size Pop is formed selecting the best individuals from the parents of the previously generation and the current offspring. The new population undergoes a new round of evaluation. For each generation of the algorithm, Pareto optimal solutions are provided. Finally, a selection operator is performed in order to reach the last front.

This cycle is repeated until the solution set does not improve, or until an individual with a desired phenotype is achieved or when the number of generation is bounded out. The number of generations D and individuals of the

population I are parameters chosen by the user. The time-complexity of the genetic algorithm is $O(2DI^r)$, where D is the number of generations, I is the population size and r is the number of the objectives. GDMO finds a set of Pareto optimal solutions (non-dominated solutions) for a combinatorial multi-objective optimisation problem, which is also a NP-complete problem.

Pareto Optimality is very useful for the analysis of metabolism, as reported in the previous works [14,15,16], where authors used multi-objective approaches to evaluate the fluxes distributions and genetic manipulations in metabolic networks. In our work, we remark the usefulness of Pareto optimality and adopt an effective and state-of-the-art algorithm to investigate the knockout space. Additionally, for the first time, we used the ϵ -dominance optimality, to do an accurate search in a neighbourhood of the edge of the Pareto region.

2.2 Pareto ϵ -Dominance

Another analysis that we perform is inspired by the idea described in [17]. They use a condition of approximated dominance for their evolutionary multi-objective algorithm with the aim of improving the diversity of solutions and convergence. We, however, use this idea to perform a post-processing analysis in order to calculate an approximated Pareto front. This calculation is designed to search for new solutions and, in particular, solutions that may have been discarded, but they are dominated by an amount that, for our purposes, can be considered negligible. Therefore, once the optimisation routine has been carried out, all the sampled points are revisited. Then, a new set of solutions is built, called " ϵ -non-dominated" set, by applying a "relaxed" condition of dominance, called ϵ -dominance. Formally, assuming that all the objective functions must be maximised, given $\epsilon > 0$, we seek all the points (solutions) belonging to the set: $\{w : w_z + \epsilon \ge u_z, \forall z = 1, ..., r\}$. Remarkably, this set contains both the new " ϵ non-dominated" solutions and the previous non-dominated ones.

2.3 FBA Modelling and the Combinatorial Optimisation Problem

FBA is a modelling framework used for studying biochemical networks and in particular the *m* metabolites and *n* reactions that are involved (e.g., their formation and degradation, transport and cellular utilisation). For each metabolite X_i , i = 1, ..., m a material balance is $\frac{dX_i}{dt} = \sum_{j=1}^n S_{ij}v_j$, where S_{ij} is the stoichiometric coefficient associated with each flux v_j , j = 1, ..., n. At steady state, $\sum_{j=1}^n S_{ij}v_j = 0$ holds. This balance equation can be written in matrix form Sv = 0, where S is the stoichiometric matrix of m rows and n columns, and v is the vector of fluxes (metabolic and transport fluxes). The matrix S is not square and n > m, so we have a plurality of solutions. Each solution is a flux distribution representing a particular metabolic state, depending on the genotype and the transport fluxes. The FBA approach finds the metabolic state in order to optimise a particular objective function, given as a linear combination of fluxes (e.g., growth rate, ATP production). Consequently, the problem can be formulated as a linear programming problem:



Fig. 1. ϵ -dominance analysis results in *E. coli* network for acetate (A) and succinate (C) multi-objective optimisation. Figures B and D report the knockout cost associated with the solutions reported respectively in Figures A and C, and the dimension of circles reflects the knockout cost associated with the solution point.

maximise (or minimise)
$$f'v$$

such that $Sv = 0$ (1)
 $v_j^L \leq v_j \leq v_j^U, j = 1, \dots, n,$

where f is a vector of weights (n dimensional). All the elements in f are either 0 or 1. In our work, f_i is equal to 1 if v_i is the biomass core, but it is possible any combination of fluxes as an objective functions. v_j^L and v_j^U are the lower and upper bound values (thermodynamic constraints) of the generic flux v_j (in our analysis, we consider $v_j^U = 100$ and $v_j^L = -100$ for the fluxes that represent reversible reactions). The output of FBA is a particular distribution of fluxes, denoted by v, which optimises the objective function. Remarkably, FBA does not describe how a certain flux distribution is realised (by kinetics or enzyme regulation), but which flux distribution is optimal for the cell.

We propose the gene-protein-reaction (GPR) mappings to allow our algorithm to work at the genetic level. GPR mappings provide links between each gene and all the reactions v_j depending on it, and define how certain genetic manipulations affect reactions in the metabolic network. For a set of L genetic manipulations, the GPR mappings are represented by a $L \times n$ matrix G, where the (l,j)-th element is 1 if the *l*-th genetic manipulation maps onto the reaction j, and is 0 otherwise.

Our approach is based on the technique adopted in OptKnock [8], which finds the fluxes distribution in the metabolic network in order to reproduce the desired productions (synthetic objectives) and achieve the maximal growth. Unlike Optknock, we are able to optimise more than one objective. The bi-level problem [8] is represented by the following formulation:

$$\begin{array}{ll} \max & g'v \\ \text{such that} & \displaystyle\sum_{l=1}^{L} y_{l} \leq C \\ & y_{l} \in \{0,1\} \\ & \max & f'v \\ & \text{such that} & Sv = 0 \\ & & (1-y)'G_{j}v_{j}^{L} \leq v_{j} \leq (1-y)'G_{j}v_{j}^{U}, \\ & & j = 1, \dots, n, \end{array}$$

$$(2)$$

where g is a vector of weights (n dimensional) associated with the synthetic objectives, and g' is its transpose. For example, when the synthetic objectives v_j and v_h have to be maximised, the weights g_j and g_h are equal to 1. y is the knockout vector (L dimensional). If there are no impaired reactions in the metabolic network, y contains only zeros. Conversely, when $y_l = 1$, the gene set involved in the manipulation l is turned off, and the corresponding reactions are in the absent status (the lower and upper bounds are set to zero, resulting in a modified metabolic network). C is an integer representing the maximum number of knockouts allowed. The bi-level problem can be converted to a MILP problem as described in [8] (for a detailed description, see the original work [8]). We implemented and solved the problem using the GLPK solver.

2.4 Sensitivity Analysis

In modelling, Sensitivity Analysis (SA) is a method used to discover which inputs play a key role on the output of the model. In the last years, scientists used SA indexes in systems biology interrogating the reactions space (RoSA - Reactions oriented Sensitivity Analysis) [18], [19] and species space (SoSA - Species oriented Sensitivity Analysis) to find their influence on the outputs of the system [20]. We perform SA to find the most sensitive inputs in FBA model of *E. coli* using the Matlab SensSB Toolbox [21].

The *E. coli* model analysed in this work contains 2382 fluxes, 299 of which represent exchange fluxes, 2082 represent inner metabolic reactions, and 1 the growth rate or biomass.

The n_{ex} exchange reactions ($n_{ex} < n$) described by the vector $v_{ex} \subset v$, allowing nutrients to enter and leave the system, are unconstrained in the forward direction (v_{ex}^U , upper bound vector), while are constrained in reverse directions (v_{ex}^L , lover bound vector) to zeros when uptake rates is not allowed. Moreover, the "*EX glc*" is an exchange reaction for glucose and has a lower bound of "-10" indicating a potential glucose uptake rate of 10 mmol gDW⁻¹ h⁻¹.

We performed the SA method considering as inputs of the model the v_{ex}^{L} lower bound vector of exchange fluxes. For each of n_{ex} exchange fluxes we varied each element of v_{ex}^L in the interval [-100, 0] of the region of interest Ω , n_{ex} -dimensional unit hypercube. We adopted the Morris [22] method in order to identify the uptake rates whose tuning results in a major system response. SA is based on the calculation of the *elementary effect* due to the variation of each input. For a given value of v_{ex}^L , we define the elementary effect of the *h*-th input as:

$$d_h(v_{ex}^L) = \frac{F(v_{ex}^L(1), \dots, v_{ex}^L(h-1), v_{ex}^L(h) + \Delta, v_{ex}^L(h+1), \dots, v_{ex}^L(n_{ex})) - F(v_{ex}^L)}{\Delta}.$$
(3)

We considered the vector of fluxes v as output $F(v_{ex}^L)$ for E. coli model, calculated by solving the problem (1). For each of the n_{ex} exchange fluxes, the attention is restricted of experimentation to \mathbf{a} region ω. n_{ex} -dimensional k-level grid, where each v_{h}^{ex} may take a value from ω $\left\{-100, -100\frac{k-2}{k-1}, \dots, -100\frac{2}{k-1}, -100\frac{1}{k-1}, 0\right\}$. Δ is a predetermined multiple of $\frac{1}{(k-1)}$ and represents the *perturbation* of the input v_h^{ex} . The distribution of elementary effects EE_h for the input v_h^{ex} is obtained by randomly sampling Q points from ω . The estimation of the mean μ^* and standard deviation σ^* of those distributions EE_h will be used as indicator of which inputs should be considered



Fig. 2. Uptake Rate-oriented Sensitivity Analysis for the *E. coli* model iAF1260. In this analysis we investigate the input fluxes of the model (299 nutrients) and evaluate their sensitivity with respect to all fluxes of the model. We find that only 70 fluxes (reported in the key) out of 299 are influent, the other ones have sensitivity indexes equal to zero. Results have been obtained averaging over 3000 evaluates of function F.

important. A high μ^* mean indicates an input with an important "overall" influence on the output. A large measure of σ^* variance indicates an input whose influence is highly dependent on the values of the inputs.

2.5 Robustness Analysis

The ability of a system to adapt to perturbations due to internal or external agents, aging, temperature, environmental changes and, in our case, also due to molecular noise and mutation is one of evolutionism guidelines and should also be a fundamental design principle. To optimise the production of a specific metabolite (and simultaneously the formation of biomass, which is necessary to maintain the survival of the bacteria), we used GDMO that obtain a *strain* that maximises the feature required by us. At this point, the validity of the biological strain, designed in-silico, must be tested as regards robustness and sensitivity to endogenous and exogenous perturbations, and this is done by the *robustness analysis*. In this way, we also know the ability of a strain to adapt to small perturbations that can occur at any stage of the biochemical processes within the bacterium, or caused by the environment in which it reproduces. As we shall see, by the term "adaptive capacity" we mean the ability to maintain "acceptable" the performances relative to the metabolite production and biomass formation previously optimised.

There are numerous methods that can be used to fulfil this task. Among these, in [23] the authors consider a big network (in this case, however, considered the Internet network) and use the theory of percolation on random graphs to test the robustness of the network in case of random or targeted node deletion, or in case of random link deletion. They associate occupation of nodes or links with their functioning, and for occupation probability they mean the probability of operation of them. They consider that this probability is uniform or depends on the degree of each node (that is the number of connections at that node) distribution. So they analyse the robustness of the network connectivity as the occupation probability is varied. Through this analysis, they highlight that a network with these characteristics is robust to random removal of nodes or links, but not if they are targeted nodes with highest degree. In another work |24|, the relationship between the general characteristics of a chemical reaction network and the sensitivity of his equilibrium is investigated according to changes in the overall supply of reagents. The authors define the sensitivity of a species as the variation of it with respect to the element concentration one, and they find a lower bound to such sensitivity that depends on the network structure alone. In particular, they argue that a strong robustness of the equilibrium against element variations is likely only if the various species are constructed from building block highly gregarious (i.e. each one binds with many others) or present in some species with high multiplicity. Finally, in [25] the authors use a combined approach of global and local robustness that they call *Glocal Robustness*. The global analysis investigates the parameter space with the aim of finding where a circuit cell shows experimental observed features (global), while the local one determines the robustness of parameter sets sampled during the previous phase.

Similar work making use of the robustness analysis for parameter estimation are also present in [26] and in [27]. In our work, however, we use very simple robustness analysis that shows a high degree of transversality because easily applicable in other fields, as was done in [28] and in [29].

The basic principle of this analysis is as follows. Firstly, we define the perturbation as a function $\tau = \gamma (\Psi, \sigma)$ where γ applies a stochastic noise σ to the system Ψ and generates a trial sample τ . The γ -function is called γ -perturbation. Without loss of generality, we assume that the noise is defined by a random distribution. In order to make statistically meaningful the calculation of robustness, we generate a set T of trial samples τ . Each element τ of the set T is considered robust to the perturbation, due to stochastic noise σ , for a given property (or metric) ϕ if the following condition is verified:

$$\rho\left(\Psi,\tau,\phi,\epsilon\right) = \begin{cases}
1, & \text{if } |\phi\left(\Psi\right) - \phi\left(\tau\right)| \le \epsilon \\
0, & \text{otherwise}
\end{cases} \tag{4}$$

where Ψ is the reference system, ϕ is a metric (or property), τ is a trial sample of the set T and ϵ is a robustness threshold. The definition of this condition makes no assumptions about the function ϕ . It can be anything (not necessarily related to properties or characteristics of the system); however, it is implicitly assumed that it is quantifiable. The robustness of a system Ψ is the number of robust trials of T, with respect to the property ϕ , over the total number of trials (|T|). In formal terms:

$$\Gamma\left(\Psi, T, \phi, \epsilon\right) = \frac{\sum_{\tau \in T} \rho\left(\Psi, \tau, \phi, \epsilon\right)}{|T|} \tag{5}$$

where Γ is a dimensionless quantity that states, in general, the robustness of a system and, in this case, of a strain.

Robustness index is a function of ϵ , so the choice of this parameter is crucial and not a trivial task. Since we are interested in the behaviour of strain when subjected to small perturbations and because the behaviour is acceptable when the deviations from the original value is as small as possible, we choose the values of epsilon equal to 1% of the metric and sigma equal 1% of the perturbed variable.

Based on this principle, we evaluate two values of robustness, the *Global Robustness* value (GR) and the *Local Robustness* value (LR). Also we evaluated the *Normalised Feasible parameter Volume* ([25]) to give a comparison between these results and the GR/LR values. The first two values only differ in the perturbation kind, in particular, chosen σ , it will differ the set of variables that will be perturbed.

Global Robustness. As regards the Global Robustness of a strain, we perturbed the upper and lower bounds of each metabolic flux. Hence, a trial τ is created by perturbing all the upper v_j^U and lower bounds v_j^L , j = 1, ..., n of the metabolic flux. We create a set T_{τ} of trials, and for each of them we perturb all the bounds and evaluate the property $\phi(\tau)$ (by flux balance analysis), which in our case can be the value of acetate, succinate, biomass or a combination of them; and then, we calculate the function ρ . Once a value of ρ is obtained for each of the trials, we compute the value of robustness (Equation 5), which in this case we call *Global Robustness* because all the parameters are perturbed.

Local Robustness. In this case, we perturb again the upper v_j^U and lower bounds v_j^L , j = 1, ..., n, of a metabolic flux, but we create a sample trial perturbing a single flux, we evaluate the property $\phi(\tau)$ and we calculate the function ρ . After creating a set T_{τ} of trials, we calculate the robustness (Equation 5), which in this case we call *Local Robustness*. Hence, we calculate a LR value for each metabolic flux.

Normalised Feasible parameter Volume. We also implemented the analysis described in [25] to compare the results obtained by GR and LR. In this analysis, the authors implement a procedure that calculates the volume occupied by those parameters such that the system maintains the desired characteristics. The volume is computed in the 2n-dimensional parameter space. In our case, the volume is such that Equation 4 holds. Since this research requires a huge computational effort, given the high number of dimensions (R^{2n} , where 2n is the number of parameters), it is guided by an iterative procedure that involves the Principal Component Analysis (PCA). In the second part, they calculate local coefficients, and from these they derive which parameters are influential on the robustness (by Spearman's partial correlation coefficient).

In particular, the first part requires two steps. The first is a Monte Carlo sampling obtained with 2n-dimensional Gaussian random variations centred around a parameter vector (known in advance). In our case this vector is represented by the 2n parameters: v_j^U and v_j^L . Then a set $T_{\tau}^{(1)}$, $2n \times K$ is created, that contains K parameter vectors. Among these, only a fraction will satisfy the Equation 4, the set comprising this fraction is the set of the feasible parameter vectors $V^{(1)}$. The second step begins with a principal component analysis of $V^{(1)}$; this analysis allows to identify statistical linear structures within high-dimension data sets. Here, instead, it is used to guide the sampling of the parameter vectors in subsequent iterations. In particular, $T_{\tau}^{(2)}$ and the subsequent sets $T_{\tau}^{(h)}$ are generated from $V^{(1)}$ and, in general, from $V^{(h-1)}$, where $h = 1, \ldots, H$ are the iterations number. In particular the generic element $\tau_{j,k}$ of $T_{\tau}^{(h)}$ is generated as:

$$\tau_{j,k} = \frac{\sum_{t^*=1}^{T^*} V_{j,t^*}^{(h-1)}}{|T^*|} + \lambda^{(h-1)} \cdot \xi_{j,k},$$
(6)

where j = 1, ..., 2n, since the columns of $T_{\tau}^{(h)}$ contain the perturbed values of the parameters v_j^U and v_j^L , j = 1, ..., n; k = 1, ..., K is the cardinality of $T_{\tau}^{(h)}$; the first term, on the right side, is the average of the elements for each perturbed parameter (that is the average for each row) of the set $V^{(h-1)}$ obtained in the previous iteration; $\xi_{j,k}$ is a Gaussian noise with zero mean and standard deviation equals to the $(j, k)^{th}$ -element of the covariance matrix $\Sigma^{(h-1)}$, i.e. the pair wise covariance calculated for all vectors τ_a and τ_b of $V^{(h-1)}$ (the eigenvectors of this matrix are the principal axes of the $V^{(h-1)}$ set by PCA); finally, the real value $\lambda^{(h-1)}$ guides the h^{th} Gaussian process by scaling the standard deviations of the distribution along the PCA directions. The purpose of Equation 6 is to avoid unnecessary sampling in a parameter space region where there are no probably feasible vectors. At the end of this procedure, a hyper-box B is constructed in the parameter space, whose axes are parallel to the PCA axes of the last iteration. The bounds of this box, for each direction, are given by the more extreme elements in the set V^H of the last iteration. Then B is uniformly sampled constructing the final set T_{τ} ; a subset V of T_{τ} will verify the Equation 4. Finally, the feasible parameter volume will be calculated as $R^{2n} = (|V| \setminus |T_{\tau}|) * Vol(B)$, where |.| determines the cardinality. The logic of this measure is that as the value of R^{2n} increases as the likelihood that perturbing a parameter vector, another feasible parameter vector is generated increases. Finally, for comparing systems with different number of parameters the normalised feasible parameter volume R is defined as $R = \sqrt{2^n R^{2n}}$. R can be considered as the *permissible average* variation per-parameter that leaves intact the system performance.

The second part of this analysis is connected to the global part. The authors take into account the final set of the feasible parameter vectors V and for each parameter vector produces Q sample trials perturbing the 2n parameters by Gaussian noise with zero mean and sigma equal to 0.2; then, they calculate the fraction of robust trials; after that, they repeat the calculations for all vectors. Finally, for the 2n-parameters, they calculate the Spearman partial correlation coefficient with respect to the robust trial fraction values and the different values assumed by the parameters $\delta_j(V(j), X)$, where $j = 1, \ldots, 2n$; V(j) is the j^{th} row of V (containing the observations of the j^{th} -parameter) and X is a vector (containing the values of the robust trial fractions).

3 Results

We tested the performance of GDMO to maximise the production of acetate and succinate in the recent model of E. coli K-12 MG1655, iAF1260 [30], and we compared it with GDLS [7], OptFlux [6] and OptGene [5]. In Table 1, we report the productions in wild type, and the results obtained by previous methods and in particular the greater level of acetate and succinate we reach. Pareto and ϵ -optimality present several suitable solutions, which are reported in details in Table 3. Our method reaches interesting results in terms of acetate, succinate, biomass and, mostly, in knockout cost. The knockout cost is defined according to the Boolean relationship between genes. For example, if a gene set is composed by two genes linked by an "AND" relation, the cost to ensure the catalysis of the corresponding reactions is 2, since both genes are necessary to turn on the reactions. Instead, the cost to ensure the turning off of the corresponding reactions (knockout cost) is 1. In our optimisation, indeed, we select as third objective the minimisation of the knockout cost, since in vivo knockout is an expensive and a difficult biotechnological procedure. In all the simulations we initialised the network with an empty set of knockouts, in order to compare our results with GDLS.

Table 1. Comparison between GDMO and previously genetic design methods. We compare OptFlux [6], OptGene [5], GDLS [7], OptKnock [8] and our multiobjective optimisation algorithm (GDMO) for maximising acetate (Ac) and succinate (Suc) production $[mmolh^{-1} gdW^{-1}]$. The third and fourth rows provide the biomass (Bm) $[h^{-1}]$ and the knockout cost (kc). We report two candidate solutions for acetate optimisation: the first strain, named A_5 (Table 3), provides a low kc equal to 3, and the second one (A_2) reaches an elevated value of acetate, +130.7%, outperforming the previous methods. For succinate production, we obtain +13659% with respect to wild type, deleting only 8 genes (B_3). The last three rows provide the robustness indexes. R values [25] and GR values are global robustness indexes. For LR we report the minimum value found that is associated with the less robust flux (glucose uptake rate). "n.a." stands for *not applicable*.

	Wilde Type	e OptFlux	OptGene	GDLS	GDLS	OptKnock	OptKnock	GDMO	GDMO	GDMO
Ac	8.30	15.129	15.138	15.914	n.a.	n.a.	12.565	13.791	19.150	n.a.
		(+82.3%)	(+82.4%)	(+91.7%)	n.a.	n.a.	(+51.4%)	(+66.13%)	(+130.7%)	n.a.
Suc	0.077	10.007	9.874	n.a.	9.727	9.069	n.a.	n.a.	n.a.	10.610
		(+12877%)	(+12704%)	n.a.	(+12514%)	(+12362%)	n.a.	n.a.	n.a.	(+13659%)
Bm	0.23	n.a.	n.a.	0.0500	0.0500	0.1181	0.1165	0.130	0.053	0.087
		n.a.	n.a.	(-78.4%)	(-78.4%)	(-77.9%)	(-49.6%)	(-43.72%)	(-77.10%)	(-62%)
kc	n.a.	n.a.	n.a.	14	26	54	53	3	10	8
GR	54.76%	n.a.	n.a.	13.76%	16.6%	43.24%	43.08%	45.32%	27.6%	40.40%
LR	54.0%	n.a.	n.a.	16.0%	21.33%	40.0%	40.60%	39.33%	24.0%	46.0%
R	1.30	n.a.	n.a.	1.45	1.45	1.18	1.02	0.78	0.44	1.32

For each solution, we also calculate the Robustness indexes. In particular the Global Robustness index (GR) can be seen as an index to discriminate a strain from each other to choose the best, as regard the robustness with respect to the selected metrics. Moreover, if GR is high, the likelihood of the strain to maintain the performance increases, even if subjected to perturbations. R values indicate the *permissible average variation per-parameter* that leaves intact the system performance. Therefore, also these values can be seen as an index to discriminate a strain from each other. If we consider the GR and R values, we can see a similar behaviour in most cases. Local Robustness (LR) index represents the absolute and relative minimum of the results obtained for each strain. Only for the flux related to D-qlucose exchange (Ex qlc), we obtain LR values less than 100%. Finally, we evaluated Spearman partial correlation coefficients. Since this procedure requires a considerable computational effort, the results of this analysis are calculated for only one strain (A4, Table 2). The results indicate that the highest value is $\delta i^* = -0.24$ (the other values are smaller at least by one order of magnitude) that corresponds to the D-glucose exchange (EX glc) reaction. It indicates that the Robustness of the strain is more correlated to this reaction. The result is identical to that we obtained with the Local Robustness analysis. Also in this case, the D-glucose exchange (EX glc) is the fragile reaction of the strain. Results are shown in Table 2.

The study of genes and reactions of E. coli has involved inferring several Pareto trade-offs in anaerobic and aerobic conditions (Figure 3 and Figure 4). The experiments reported in Figure 3 show that GDMO overcomes all the above mentioned methods, and in particular GDLS. The latter performs a single-objective optimisation maximising the synthetic objective function acetate



Fig. 3. Maximisation of biomass and acetate production in anaerobic and aerobic conditions (A,B), and maximisation of biomass formation and succinate production in anaerobic and aerobic Condition (C,D), with glucose uptake rate 10 mmolh⁻¹ gDW⁻¹ in iAF1260. In black the Pareto solutions obtained by GDMO, and in red the optimal results obtained by GDLS [7].

production with knockout cost equal to 14, or optimising succinate production with knockout cost 26, as shown in Table 1 and Figure 3.

The Pareto front strategy is useful to investigate the biological and statistical complexity in several organisms. Figure 5 reports four Pareto curves obtained optimising the acetate/succinate production and the biomass formation in different organisms: the E. coli [30], the Methanosarcina barkeri [11], Geobacter sulfurreducens [10] and Yersinia pestis [12]. M. barkeri is an archaea able to live in anaerobic condition and produce methane using three known metabolic pathways for methanogenesis. Geobacter species are of ecological importance due to bioremediation capabilities. The organism can metabolise uranium, has the ability to generate electricity and can decompose petroleum contaminants in polluted groundwater. For all the organisms, glucose uptake rate is fixed at a maximum of 10 $mmolh^{-1}qDW^{-1}$ as a carbon source (except for *M. barkery*, which does not features the glucose exchange flux in its metabolic network). Some external metabolites (e.g., calcium, ammonia, sulfate, phosphate, oxygen, water, proton, iron (II-III), potassium, sodium, copper, chloride and carbon dioxide) are allowed to both enter and leave the system, while the others are allowed only to leave the system. GDMO highlights the response of different systems and the ability of the organisms to produce the desired metabolite. In the same conditions, M. barkeri and G. sulfurreducens reach higher levels of acetate than E. coli.

Table 2. Robustness analysis results. For each strain we report: the *Global Robustness Value* (GR), the *normalised feasible parameter volume* (R) and the *Local Robustness* (LR) values. For the LR values are shown the minimum associated with the glucose uptake rate. For all other fluxes, we obtained 100% of local robustness.

Strain	$\mathbf{GR}(\%)$	R	LR(%)
A_1	28.72	0.39	26.67
A_2	27.60	0.44	24.00
A_3	40.72	1.27	35.33
A_4	41.52	1.74	36.0
A_5	45.32	0.78	39.33
B_1	44.60	0.15	44.67
B_2	43.48	0.92	42.0
B_3	40.40	1.32	46.0
B	44.64	1.30	44.0



Fig. 4. Pareto fronts for six optimisation problems. We simultaneously maximise biomass formation $[h^{-1}]$ and A) ATP synthase rate, B) 1,2-propanediol, C) CO₂, D) ethanol, E) formate , F) lactate production rates $[mmolh^{-1} \text{ gDW}^{-1}]$. In blue we simulate aerobic conditions with O₂=10 mmolh⁻¹ gDW⁻¹, in black anaerobic conditions.

Table 3. We report some of the proposed solutions obtained by GDMO to maximise acetate and succinate productions $[mmoh^{-1} gDW^{-1}]$ in *E. coli* network. For each strategy, we report the biomass formation $[h^{-1}]$, the knockout cost (k cost) and the corresponding genes and reactions switched off. The variation of acetate, succinate and biomass in comparison with the wild type is enclosed in brackets.

- A	Strain	Acetate	Biomass	k cost	Knocked out Genes	Deleted Beactions
* (131.26%) (-77.38%) (b0010) · cytoplate kinase (CAXP) Cytoplate kinase (CAXP) · (130.26%) (-77.38%) (b3603) cytoplate kinase (CAXP) cytoplate kinase (CAXP) · (-8313) (-101.10) (-101.10) cytoplate kinase (CAXP) cytoplate kinase (CAXP) · (-130.7%) (-77.10%) (-101.10) cytoplate kinase (CAXP) cytoplate kinase (CAXP) · (-130.7%) (-77.10%) (-101.10) cytoplate kinase (CAXP) cytoplate kinase (CAXP) · (-130.7%) (-77.10%) (-101.10) cytoplate kinase (CAXP) cytoplate kinase (CAXP) · (-130.7%) (-77.10%) (-101.10) cytoplate kinase (CAXP) cytoplate kinase (CAXP) · (-130.7%) (-58.6%) (-101.10) cytoplate kinase (CAXP) cytoplate kinase (CAXP) · (-131.27%) (-58.6%) (-101.10) cytoplate kinase (CAXP) cytoplate kinase (CAXP) · (-131.27%) (-58.6%) (-101.10) cytoplate kinase (CAXP) cytoplate kinase (CAXP) ·	A ₁	19.198	0.052	12	(b0351) OR (b1241)	acetaldehyde dehydrogenase (acetylating)
ki 2753 OR (b3603) Cyttidylate kinase (GMP) biastet transport via proton symport. reversible transport via symport. reversible transport via proton symport. reversible transport via proton symport. reversible transport via sy	-	(131.26%)	(-77.38%)		(b0910)	cytidylate kinase (CMP)
A2 19.150 0.06303 Didatas transport via proton symptor (FdH* and Hyd4) or (FdH* and Hyd5) A2 19.150 0.053 10 Didatas transport via proton symptor (b3617) A3 19.150 0.053 10 Didatas transport via proton symptor (b3617) A4 19.150 0.053 10 Didatas transport via proton symptor (b3617) A3 19.532 0.066 0.053 Didatas transport via proton symptor (b3617) C130.7%) (-77.10%) Didatas transport via proton symptor (b3617) Didatas transport via proton symptor (b3617) C133.2%) (-58.6%) Didatas transport via proton symptor (b3630) Didatas transport via proton symptor (b3631) A4 14.046 0.066 Didatas transport via proton symptor (b3631) Didatas transport via proton symptor (b3631) A5 10.532 Didatas transport via proton symptor (b3631) Didatas transport via proton symptor (b3631) A4 14.046 0.104 5 b0531) Didatas transport via proton symptor (b3631) A5 13.791 0.130 3 b0531) Didatas transport via proton symptor (b3631) Didatas transport vi						cytidylate kinase (dCMP)
A2 10.150 (b4381) (FdhF and Hyd4) or (FdhF and Hyd9) Format-bydrogen lyses glutamet-s-semilaldyde dehydrogenase (b40963) A2 19.150 0.053 10 (b531) (K (b124)) aestaldbyde dhydrogenase glutamet-s-semilaldyde dehydrogenase (b40963) A2 19.150 0.053 10 (b531) (K (b124)) aestaldbyde dhydrogenase (b4381) (130.7%) (77.10%) (b331) (K (b124)) aestaldbyde dhydrogenase (b4381) D-Lactaldbyde dhydrogenase (b4381) (130.7%) (77.10%) (b331) (K (b124)) aestaldbyde dhydrogenase (b4381) D-Lactaldbyde dhydrogenase (b4017) (132.2%) (-58.9%) (b331) (K (b124)) aestaldbyde dhydrogenase (b4381) D-Lactaldbyde dhydrogenase (b4017) (123.2%) (-58.9%) (b331) (K (b124)) aestaldbyde dhydrogenase (b4023) D-Lactaldbyde dhydrogenase (b4023) (123.2%) (-58.9%) (b3630) D-Lactal dehydrogenase (b4023) D-Lactal dehydrogenase (b4024) (123.7%) (-58.9%) (b3631) (K (b1241) aestaldbyde dhydrogenase (b4049) aestaldbyde dhydrogenase (b4025) (123.7%) (-58.9%) (b1531) (K (b1241) aestaldbyde dhydrogenase (b4049) aestaldbyde dhydrogenase ((b2975) OR (b3603)	D-lactate transport via proton symport
(bd381) (FdBF and Hyd4) or (PdhF and Hyd9) Formato-shydrogen lyase glutamice-s-semilaldyde dehydrogenase averaging lycosel sympase (bd381) Formato-s-semilaldyde dehydrogenase averaging lycosel sympase (bd381) A2 19.150 0.053 10 (bd31) Sactaldyde dehydrogenase (bd331) Sactaldyde dehydrogenase (bd331) A3 130.7%) (-77.10%) 10 (bd31) Sactaldyde dehydrogenase (bd331) A3 18.532 0.066 9 (bd31) Sactaldyde dehydrogenase (bd320) A3 18.532 0.066 9 (bd31) Sactaldyde dehydrogenase (bd320) A4 14.046 0.104 5 (bd31) Sactaldyde dehydrogenase (bd320) A4 14.046 0.104 5 (bd31) Sactaldyde dehydrogenase (bd320) A5 13.791 0.133 6 (bd31) Sactaldyde dehydrogenase (bd220) A5 13.791 0.133 10 (bd21) Sactaldyde dehydrogenase (bd220) (bd210) (bd221) Sactaldyde dehydrogenase (bd220) Sactaldyde dehydrogenase (bd220) 13.791 0.130 10 1						L-lactate reversible transport via proton symport.
(FdhF and Hyd4) or (FdhF and HycB) Formats-hydrogen lyses (10043) glutamate-semialdolyde dolydrogenase (13017) A2 19.150 0.053 10 (b531) OR (b1241) asstaldolyde dolydrogenase (1430,7%) (77.10%) A2 19.150 0.053 10 (b531) OR (b1241) asstaldolyde dolydrogenase (b4381) (FdhF and Hyd4) or (FdhF and HycB) Formats-hydrogen lyses (1300,7%) (FdhF and Hyd4) or (FdhF and HycB) Formats-hydrogen lyses (b4381) A3 18.552 0.006 0 (b531) OR (b1231) asstaldolyde dolydrogenase (cacetyltransferase (b4381) A3 18.552 0.006 0 (b531) OR (b1231) cacetaldolyde dolydrogenase (cacetyltransferase (b4381) cacetaldolyde dolydrogenase (cacetyltransferase (b4383) cacetaldolyde dolydrogenase (cacetyltransferase (b4383) cacetaldolyde dolydrogenase (cacetaldolyde dolydrogenase (b4381) cacetaldolyde dolydrogenase (cacetaldolyde dolydrogenase (cacetaldolyde dolydrogenase (b4380) cacetaldolyde dolydrogen					(b4381)	deoxyribose-phosphate aldolase
(b0243) glutamate 5-semilabyte dehydrogenase glutamate 5-semilabyte dehydrogenase (b331) OR (b1241) glutamate 5-semilabyte dehydrogenase actual dehydrogenase (b331) OR (b1241) A2 10.150 0.053 10 (b331) OR (b1241) actual dehydrogenase (b331) OR (b1241) A3 10.552 (b344) (Fd18F and Hyd) or (FdhF and Hych) Formate-hydrogen lysase (b3236) A3 18.532 0.006 9 (b331) OR (b1241) actataldhydrogenase (actylating) optime-phosphate allolase (b3236) A3 18.532 0.006 9 (b331) OR (b1241) actataldhydrogenase (actylating) optime-phosphate allolase (b3236) (b2975) OR (b3603) (b3631) OR (b1241) actataldhydrogenase (actylating) optime-phosphate allolase (b3817) optime-phosphate allolase (b3817) (b2975) OR (b3603) (b351) OR (b1241) actataldhydrogenase (actylating) dbydrogenase (actylating) dbydrogenase (actylating) dbydrogenase (actylating) dbydrogenase (actylating) dbydrogenase A4 14.046 0.104 5 (b351) OR (b1241) actataldhydrogenase (actylating) dbydrogenase (actylating) dbydrogenase A5 13.791 0.130 3 (b351) OR (b1241) actataldhydrogenase dbydrogenase B1 12.12 <td< td=""><td></td><td></td><td></td><td></td><td>(FdhF and Hyd4) or (FdhF and HycB)*</td><td>Formate-hydrogen lyase</td></td<>					(FdhF and Hyd4) or (FdhF and HycB)*	Formate-hydrogen lyase
(b301) gyran C-acetyl transferase Nuo' A2 19.150 0.053 10 (b304) NADH dehydrogenase (b304) A2 19.150 0.053 10 (b31) acetaldehyde dehydrogenase (b304) A3 18.532 0.066 9 (b351) OR (b2133) Primate-hydrogenase (b1360) A3 18.532 0.066 9 (b351) OR (b1213) acetaldehyde dehydrogenase (acetylating) cytidylate kinase (CMP) (123.2%) (-58.6%) (b0010) acetaldehyde dehydrogenase (acetylating) cytidylate kinase (CMP) (123.2%) (-58.6%) (b0010) acetaldehyde dehydrogenase (acetylating) cytidylate kinase (CMP) (123.2%) (-58.6%) (b0010) acetaldehyde dehydrogenase (acetylating) cytidylate kinase (CMP) (123.2%) (-58.6%) (b0131) acetaldehyde dehydrogenase (acetylating) cytidylate kinase (ACMP) (14.046 0.104 6 (0351) OR (b1241) acetaldehyde dehydrogenase (b409) (66.13%) (-4.4.72%) 3 (b150) Tryptophase dehydrogenase (b257) Tryptophase dehydrogenase (b409) B1 <td< td=""><td></td><td></td><td></td><td></td><td>(b0243)</td><td>glutamate-5-semialdehyde dehydrogenase</td></td<>					(b0243)	glutamate-5-semialdehyde dehydrogenase
Number Number (130.7%) Number (130.7%) Number (140.7%) Num					(b3617) (b0062)	glycine C-acetyltransferase
A2 19.180 0.053 10 (b334) actaldehyd aldydrogenase (acetylating) aldose reductase (acctol) (J30.7%) actaldehyd aldydrogenase (L4381) (130.7%) (-77.10%) 10 (b334) actaldehyd aldydrogenase (L4381) (H4381) (H4381) (H4381) (H4381) (H4381) (H330) 0.06 (D1330) (D1 (H124)) actaldehyd aldydrogenase (H404) are (H124) A3 18.532 0.096 (H2330) malate dhydrogenase (H404) are (H124) D-lactate dhydrogenase (H404) are kinase (dCMP) (122.2%) (-58.6%) (H2631) actaldehyd aldydrogenase (H404) are kinase (dCMP) (L4381) (H275) OR (H124) actaldehyd aldydrogenase (H404) are kinase (dCMP) (L4381) (H2631) actaldehyd aldydrogenase (H404) are kinase (dCMP) D-lactate trapport i a proton a symport, rev (H4381) (H4381) (H4381) (H4381) actaldehyd aldydrogenase (H404) are kinase (dCMP) (H4381) (H303) OR (H1241) actaldehyd aldydrogenase (H4381) (H4381) (H4381) actaldehyd aldydrogenase (H317) actaldehyd aldydrogenase (H317) (H4381) (H					(10903) Nuo*	NADH dehydrogenase
(130.7%) (-77.10%) (b.3945) aldose reductase (acciol) Glycerol dehydrogenase Glycerol dehydrogenase (-4381) A3 18.532 0.006 9 (b.3230) D-Lactaldehydrogenase glycine C-accylytansferase glycine C-accylytansferase (-5303) A3 18.532 0.006 9 (b.2330) malate dehydrogenase malate dehydrogenase (-58.6%) A3 18.532 0.006 9 (b.2013) protein (-58.0%) (123.2%) (-58.6%) 9 (b.3603) D-Lactate dehydrogenase malate dehydrogenase (-69.2%) (130.7%) (-58.6%) 9 (b.3617) cytick anaport via proton symport glycolate transport via proton symport glycolate transport via proton symport glycolate transport via proton symport glycolate dehydrogenase nuo A4 14.046 0.104 5 (b.3017) acctaldehyde dehydrogenase glycone C-accylytansferase glycone C-accylytansferase glycone C-accylytansferase (b.4381) A5 13.701 0.130 3 (b.0317) acctaldehyde dehydrogenase glycone c-accylytanse (b.4303) A5 13.701 0.130 3 (b.0311) acctaldehyde dehydrogenase glycone c-accylytanse glycone c-accylytanse glycone c-accylytanse glycone c-accylytanse glycone c-accylyta	A ₂	19.150	0.053	10	(b0351) OR (b1241)	acetaldehyde dehydrogenase (acetylating)
Glycerol delytyder:NAD+1-oxidoreductase Charactaldalyder:NAD+1-oxidoreductase (H381) (Pd1F and Hyd4) or (Pd1F and Hyd2) (H380) OR (D2133) A3 18.532 (122.2%) 0.096 (123.2%) 0.096 (122.2%) (-56.6%) (122.2%) (-56.6%) (122.2%) (-56.6%) (122.2%) (-56.6%) (123.2%) (-56.6%) (123.2%) (-56.6%) (123.2%) (-56.6%) (123.2%) (-56.6%) (123.2%) (-56.6%) (123.2%) (-56.6%) (123.2%) (-56.6%) (123.2%) (-56.6%) (123.2%) (-56.6%) (123.2%) (-56.6%) (123.2%) (-56.6%) (123.2%) (-56.6%) (123.7%) (-60.31) (14871) -56.74% (13708) (-124.16) (1371) 0.102 (1372) (-60.51) (1373)	-	(130.7%)	(-77.10%)		(b3945)	aldose reductase (acetol)
4.3 10-1actated pydei:AD+ 1-oxidorediretase (b3817) 0.1actated pydei:AD+ 1-oxidorediretase (b380) A3 18.532 0.066 9 (b331) D-1actate delydrogenase (b3236) prime - oxydepsile (b331) D-1actate delydrogenase (acetylating) A3 18.532 0.066 9 (b331) Chartate delydrogenase (b3236) D-1actate delydrogenase (acetylating) A3 (128.2%) (-58.6%) (b031) Chartate transport via proton symport, glycolate tr						Glycerol dehydrogenase
Cristing					(h 4981)	D-Lactaldehyde:NAD+ 1-oxidoreductase
Kurster Byteine Construction A3 18.532 0.006 9 (b330) OR (b2133) D-lactate dehydrogenase A3 18.532 0.006 9 (b331) OR (b1241) acetaldehydr dehydrogenase (126.23%) (-58.6%) (b931) OR (b213) acetaldehydr dehydrogenase (acetylating) (126.23%) (-58.6%) (b931) (b931) (b931) (b931) (b4381) (b9205) (b4381) (b9205) (b1241) (acetylating) (b4381) (b4381) (b432) (b432) (b432) (b440) (b432) (b303) (b1241) acetaldehydr ogenase (acetylating) (b433) (b31) (b1241) acetaldehydr ogenase (acetylating) (6.13%) (-43.72%) (b133) (b1241) acetaldehydr ogenase (acetylating) (12476%) (-76.33%) (b133) (b1241) acetaldehydr ogenase (acetylating) (12476%) (-76.33%) (b1241) acetaldehydr ogenase (acetylating) (124					(FdhF and Hvd4) or (FdhF and HvcB)*	Formate-hvdrogen lvase
Kata (b1380) OR (b2133) D-lactate dehydrogenase mathed dehydrogenase (construction) A3 18.532 0.096 9 (b3236) mathed dehydrogenase (construction) A3 18.532 0.096 9 (b3216) construction) A3 18.532 0.096 9 (b301) construction) (123.2%) (-58.6%) (b400) construction) construction) (123.2%) (-58.6%) (b4381) construction) construction) (b4381) (b4381) decoxribose-phosphate aldolase construction) (b438) (b4381) construction) construction) construction) (b4025) (b310) (b1241) construction) construction) (b4025) (b139) construction) construction) construction) B1 12.012 0.055 15 (b0371) OR (b1241) construction) (15476%) (-76.33%) (b2551) construction) constructions B1 12.012 0.055 15 (b0370					(b3617)	glycine C-acetyltransferase
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$					(b1380) OR (b2133)	D-lactate dehydrogenase
A3 18.532 0.096 9 (b0910) cp: (b131) cp: (b131) <thcp: (b131)<="" th=""> <thcp: (b131)<="" th=""> cp:</thcp:></thcp:>					(b3236)	malate dehydrogenase
(123.2.4) (-93.0.6) (10010) b) (10010) b) (10010) (b) (123.2.4) (-93.0.6) (10010) b) (10010) (b) (123.2.4) (b) (2010) (b) (2010) (b) (2010) (b) (123.2.4) (b) (2010) (b) (2010) (b) (2010) (b) (2010) (b) (2010) (b) (2010) (b) (2010) (b) (2010) A4 (14.0.46) 0.104 5 (b) (2010) (b) (2010) (b) (2010) (c) (-55.14%) (b) (2010) (b) (2010) (b) (2010) (b) (2010) (c) (-55.14%) (b) (2010) (b) (2010) (b) (2010) (c) (c) (c) (c) (-55.14%) (b) (2010) (b) (2010) (b) (2010) (c)	A ₃	18.532	0.096	9	(b0351) OR (b1241)	acetaldehyde dehydrogenase (acetylating)
(b2975) OR (b3603) D-heatre transport via proton symport, rev locate transport via symport in symport via symport locate transport via symport via symport locate transport via symport via symport via symport locate transport via symport via symport via symport locate transport via symport via symport via symport via symport via symport locate transport via symport via sympo		(123.270)	(-38.070)		(00910)	cytidylate kinase (CMP)
A4 14.046 0.104 5 (b3817) (b0603) methylglyxal synthase A4 14.046 0.104 5 (b3017) astaldahyde dehydrogenase methylglyxal synthase A4 14.046 0.104 5 (b3020%) (-55.14%) (b3017) astaldahyde dehydrogenase (b5317) astaldahyde dehydrogenase astaldahyde dehydrogenase A5 13.791 0.130 3 (66.13%) (-43.72%) (b1539) astaldahyde dehydrogenase B1 12.012 0.055 15 (b0351) OR (b1241) astaldahyde dehydrogenase B1 12.012 0.055 15 (b1530) Deleted Reactions B1 12.012 0.055 15 (b2587) 2-caoglutartare reversible transport via sym (15476%) (-76.33%) (b2587) 2-caoglutartare reversible transport via sym (b4849) (b2681) astaldahyde dehydrogenase Latine transminase alanite transminase Latine transminase Latine transminase (b1849) (b2681) methylglyxal synthase (b2661) (b263) methylglyxal synthase (b1849) (b2661) sucinat-semineladolase (b1482) <					(b2975) OR (b3603)	D-lactate transport via proton symport
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$						glycolate transport via proton symport, reversible
bill (bild) decyr)Dose-phosphate aldolase glycine C-acetyltansferase methylgboxal synthase A4 (40.46) 0.104 5 (bild) methylgboxal synthase A4 (69.20%) (-55.14%) 5 (bild) methylgboxal synthase (69.20%) (-55.14%) 5 (bild) methylgboxal synthase (64.13%) (-43.72%) (bild) methylgboxal synthase methylgboxal synthase (66.13%) (-43.72%) (bild) (bild) methylgboxal synthase methylgboxal synthase B1 12.012 0.055 15 (bild) methylgboxal synthase L-argit dehydrogenase B1 12.012 0.055 15 (bild) (bild) methylgboxal synthase (bild) (-76.33%) (bild) (bild) methylgboxal synthase methylgboxal synthase (bild) (bild) (bild) (bild) methylgboxal synthase methylgboxal synthase (bild) (c-76.33%) (bild) (bild) methylgboxal synthase methylgboxal synthase (bild)					(L-lactate reversible transport via proton symport
Image: Strain Succinate Biomass k cost Knocked out Genes Deleted Reactions B1 12.012 0.055 0R (b213) cstablebyde dehydrogenase (acetylating) B1 12.012 0.055 15 (b30) Choole (b213) B1 12.012 0.055 15 (b310) Choole (b213) B1 13.791 0.055 15 (b30) Choole (b213) cstablebyde dehydrogenase (acetylating) B1 12.012 0.055 15 (b310) Choole (b213) cstablebyde dehydrogenase (acetylating) (15476%) (-76.33%) 15 (b303) Choole (b251) cstablebyde dehydrogenase B1 12.012 0.055 15 (b313) cstablebyde dehydrogenase cstablebyde dehydrogenase (15476%) (-76.33%) 15 (b310) Chuore (b213) cstablebyde dehydrogenase cstablebyde de					(b4381) (b3617)	deoxyribose-phosphate aldolase
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $					(b0963)	methylglyoyal synthase
A4 14.046 0.104 5 (b0351) OR (b1241) (b4025) acetaldehyde dehydrogenase (acetylating) glycine Cacetyltransforase (b40708) A5 13.791 0.130 3 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) A5 13.791 0.130 3 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) B1 12.012 0.055 15 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) B1 (15476%) (-76.33%) 15 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) Classe (b1870) OR (b2551) acetaldehyde dehydrogenase (acetylating) D-alarine transminase alanine transaminase B1 12.012 0.055 15 (b0370) OR (b2551) D-alactate dehydrogenase (acetylating) Classe (b1840) (b1840) GAR transformylase-T D-lactate dehydrogenase (NA (b1840) (b1380) OR (b2133) (b1602 AND b1603) NAD(P) transhydrogenase (certylating) (14875%) (-69.3%) (b330) OR (b1241) acetaldehyde dehydrogenase (neetylating) (14875%) (-69.3%) (b1602 AND b1603) </td <td></td> <td></td> <td></td> <td></td> <td>Nuo</td> <td>NADH dehydrogenase</td>					Nuo	NADH dehydrogenase
(69.20%) (-55.14%) (b3617) (b4025) (b3708) glycine C-actyltransferase glycone C-phosphate isomerase Tryptophanase (L-tryptophan) A5 13.791 0.130 (b0351) OR (b1241) actaldehyde dehydrogenase L-serine dehydrogenase (b1539) Strain Succinate Biomass k cost Knocked out Genes Deleted Reactions B1 12.012 0.055 15 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) 2-ocoglutartar erversible transaminase alanine transaminase B1 12.012 0.055 15 (b0370) OR (b2551) Dalatine transaminase (b1840) B1 12.012 0.055 15 (b0370) OR (b2133) D-lactate dehydrogenase (acetylating) B2 (b1852) (b1852) glucose 6-phosphate dehydrogenase (b1840) GAR transform/jase-T (b1380) OR (b2133) D-lactate dehydrogenase (L-serine) (b2461) matcygenase (L-serine) succinate-semialdehyde dehydrogenase (AADP) B2 11.530 0.070 10 (b0551) OR (b1241) acetaldehyde dehydrogenase (b2463) B3 10.610 0.087 8 (b10351) OR (b1241) acetaldehyde dehydrogenase (b2463) B3 10.610 0.087 8 (b1002 AND b1603) D-lactate dehydrogenase (b2463) B4 9.284 0.093 5 (b0351) OR (b1241) <td< td=""><td>A₄</td><td>14.046</td><td>0.104</td><td>5</td><td>(b0351) OR (b1241)</td><td>acetaldehyde dehydrogenase (acetylating)</td></td<>	A ₄	14.046	0.104	5	(b0351) OR (b1241)	acetaldehyde dehydrogenase (acetylating)
(b4025) glucose-6-phosphate isomerase Tryptophanase (L-tryptophana) A5 13.791 0.130 3 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) Iscorinate Biomass k cost Knocked out Genes Deleted Reactions B1 12.012 0.055 15 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) (15476%) (-76.33%) (b2587) 2-oxoglutarate reversible transport via sym Dalaine transminase Lalio Threonine Aldolase Threonine Aldolase (b1852) (b1852) GAR transformylase-T (b1840) GAR transformylase-T Dalattae dehydrogenase (Desphate dehydrogenase (b1840) (b4388) phosphoserine phosphates (L-serine) (b2661) (b3403) malic enzyme (NADP) (b1602 AND b1603) NAD(P) transhydrogenase (periplasm) (14875%) (-60.3%) (b2587) (13630) OR (b2133) D-lactate dehydrogenase (priplasse) (14875%) (-60.3%) (b2587) 2-oxoglutarate transport via sympott (14875%) (-60.3%) (b2587) 2-oxoglut		(69.20%)	(-55.14%)		(b3617)	glycine C-acetyltransferase
A5 13.791 0.130 3 (b3708) 17yptopnamase (1-tryptopnam) A5 13.791 0.130 3 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) (66.13%) (-43.72%) 3 (b1539) Lallo-threonine dehydrogenase Strain Succinate Biomass k cost Knocked out Genes Deleted Reactions B1 12.012 0.055 15 (b1351) OR (b1241) acetaldehyde dehydrogenase (acetylating) Lastrine dohydrogenase (acetylating) 2-oxogUutarate reversible transport via sym (b1570) (b1580) OR (b2551) D-alanine transaminase Lallo-Threonine Aldolase Thronine aldolase Threonine aldolase (b1840) (b1380) OR (b2133) Datarate reversibe transport via sym (b4388) phosphoserine phosphates (L-tryptopnam) (b4388) B2 11.530 0.070 10 (b0351) OR (b1241) acetaldehyde dehydrogenase (periplasm) (b4708) (-69.3%) (b4385) phosphoserine phosphates (L-tryptopnam) B2 11.530 0.070 10 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) (14875%) (-69.3%) (b4385) phosphoserine phosphatese (periplasm) Tryptophana) <t< td=""><td></td><td></td><td></td><td></td><td>(b4025)</td><td>glucose-6-phosphate isomerase</td></t<>					(b4025)	glucose-6-phosphate isomerase
A5 (6.13%) (-43.72%) (b1519) (b1521) (b1521) Strain Succinate Biomass k cost Knocked out Genes Deleted Reactions B1 12.012 0.055 15 (b1351) OR (b1241) acetaldehyde dehydrogenase (acetylating) 2-xoxglutarate reversible transport via sym Delated Reactions Delated Reactions B1 12.012 0.055 15 (b0351) OR (b2551) Delated dehydrogenase (acetylating) 2-xoxglutarate reversible transport via sym Delated Reactions Delated dehydrogenase (acetylating) (b476%) (-76.33%) (b1852) glucose 6-phosphate dehydrogenase (acetylating) (b1849) GAR transformylase-T Delated dehydrogenase (b1849) Delated eloydrogenase (b1849) (b1849) malic enzyme (NADP) methydrogenase (b2661) methydrogenase (certiplasm) (b1602 AND b1603) malter-semialdehyde dehydrogenase (b287) acetaldehyde dehydrogenase (acetylating) (14875%) (-69.3%) (b2381) OR (b1241) acetaldehyde dehydrogenase (acetylating) (14875%) (-69.3%) (b2381) OR (b1241) acetaldehyde dehydrogenase (acetylating)	A	19 701	0.120		(b3708) (b3708)	Iryptophanase (L-tryptophan)
International Strain Description (Sector) Description (Sector) Strain Succinate Biomass k cost B1 12.012 0.055 15 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) b1 (15476%) (-76.33%) (b2587) Deleted Reactions b2 (15476%) (-76.33%) (b0870) OR (b2551) Deleted Reactions b2 (b1852) (b1849) Deleted Reactions b2 (b1852) (b1849) GAR transformylase-T (b1840) OR (b2133) Deleted dehydrogenase (Desphate dehydrogenase (b2463) (b2661) (b1602 AND b1603) malic enzyme (NADP) (b2661) (b1602 AND b1603) NAD(P) transhydrogenase (periplasm) (14875%) (-69.3%) (b2581) acetaldehyde dehydrogenase (b1380) OR (b2133) (b2463) malic enzyme (NADP) (b1602 AND b1603) NAD(P) transhydrogenase (periplasm) Tryptophanas (14875%) (-69.3%) (b2581) 2-oxoglutarate transport via symport (b3708) D-Lactate dehydrogenase (b1852) Bacetaldehyde dehydrogenase (14875%) (-69.3%) (b2581) 2-oxoglutarate transport via symport (b3708) D-Lactate dehydrogenase D-Lactaldehyde:NAD+ 1-oxi	A5	(66.13%)	(-43.72%)	3	(b1539)	L-allo-threenine dehydrogenase
Strain Succinate Biomass k cost Knocked out Genes Deleted Reactions B1 12.012 0.055 15 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) (15476%) (-76.33%) (b0350) OR (b2551) acetaldehyde dehydrogenase (acetylating) (15476%) (-76.33%) (b1852) glucose acetaldehyde dehydrogenase (acetylating) (b1852) (b1852) glucose GAR transform/lase-T Threnoine aldolase (b1852) (b1853) OLactate dehydrogenase MADP) (b1854) (b1853) malte cnaryme (NADP) (b2663) mathylglyxxal synthase (b0963) (b2678) (b0351) OR (b213) NADP(P) transhydrogenase (acetylating) (b4785) (-69.3%) 10 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) 2 11.530 0.070 10 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) (14875%) (-69.3%) 10 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) (14875%) (-69.3%)		(00.2070)	(()	D-serine dehydrogenase
Strain Succinate Biomass k cost Knocked out Genes Deleted Reactions B1 12.012 0.055 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) (15476%) (-76.33%) (b0870) OR (b2551) Dalate acetaldehyde dehydrogenase (acetylating)						L-serine dehydrogenase
B1 12.012 0.055 15 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) (15476%) (-76.33%) (b0370) OR (b2551) Dalanine transaminase (b0870) OR (b2551) Dalanine transaminase (b1840) GAR transominase (b1840) GAR transformjase-T (b1840) GAR transformjase-T (b1840) Dalate dehydrogenase (b1840) GAR transformjase-T (b1840) Dalate dehydrogenase (b1840) OR (b2133) (b1602 AND b1603) NAD(P) transhydrogenase (acetylating) (b1602 AND b1603) NAD(P) transhydrogenase (acetylating) (b1380) OR (b1241) acetaldehyde dehydrogenase (acetylating) (b1380) OR (b1241) acetaldehyde dehydrogenase (acetylating) (b13945) (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) (14875%) (-69.3%) (b1520) Quartate transport via symport (b1300) OR (b2133) D-Lactatdehyde dehydrogenase (NADP) (b1360) OR (b2133) D-Lactate dehydrogenase (NADP) (b1360) OR (b2133) acetaldehyde dehydrogenase (NADP) (b1360) OR (b2133) acetaldehyde dehydrogenase (NADP) (b1369%) (-62%) (b10301) OR (b1241) acetaldehyde dehydrogenase <th>Strain</th> <th>Succinate</th> <th>Biomass</th> <th>k cost</th> <th>Knocked out Genes</th> <th>Deleted Reactions</th>	Strain	Succinate	Biomass	k cost	Knocked out Genes	Deleted Reactions
(1910) (1900) (1900) (1900) Delanine transaminase alanine transaminase Lallo-Thrennine Aldolase Thrennine Aldolase (b1852) (b1852) (b1852) glucose 6-phosphate dehydrogenase (b2463) (b1840) D-lactate dehydrogenase (b2463) Delactate dehydrogenase (b2463) (b1852) malic emyme (NADP) (b1852) malic emyme (NADP) (b1852) malic emyme (NADP) (b2661) phosphoserine phosphatase (L-serine) (b2661) mothology (b1857) (b1851) (b1857) (b1852) (b2661) mothology (b2661) mothology (b1852) mothology (b1852) mothology (14875%) (-69.3%) (b1852) 2-coxoglutarate transport via symport (b1852) malic enzyme (NADP) (b1852) D-lactate dehydrogenase (b1852) D-lactate dehydrogenase (b1852) D-lactate dehydrogenase (b1852) malic enzyme (NADP) (b1852) D-lactate dehydrogenase (b1852) malic enzyme (NADP) (b263) malic enzyme (NADP) (b263) malic enzyme (NADP) (b263) malic enzyme (NADP) (b1360) AND b1603) NAD(P) </td <td>в1</td> <td>(15476%)</td> <td>0.055 (-76.33%)</td> <td>15</td> <td>(b0351) OR (b1241) (b2587)</td> <td>acetaldehyde dehydrogenase (acetylating)</td>	в1	(15476%)	0.055 (-76.33%)	15	(b0351) OR (b1241) (b2587)	acetaldehyde dehydrogenase (acetylating)
B2 11.530 0.070 10 (bi380) OR (bi213) OR (bi203) B2 11.530 0.070 10 (bi380) OR (bi213) OR (bi203) B2 11.530 0.070 10 (bi380) OR (bi213) OR (bi203) B2 11.530 0.070 10 (bi380) Polactate dehydrogenase (Deriplasm) (14875%) (-69.3%) (bi380) Tryptophanase (L-tryptophana) (13876%) (-69.3%) (bi2031) Contrastret dehydrogenase (acetylating) (14875%) (-69.3%) (bi380) OR (bi213) (13659%) (-69.3%) (bi380) OR (bi213) (13659%) (-62%) 8 (bi0351) OR (bi213) (13659%) (-62%) (bi0351) Chi213) D-lactate dehydrogenase (bi380) OR (bi213) malic enzyme (NADP) NAD(P) (13659%) (-62%) ((bi3901) acetaldehyde dehydrogenase (bi380) OR (bi213) malic enzyme (NADP) (bi380) (bi3903) D-lactate dehydrogenase (bi380) (bi3903) D-lactate dehydrogenase (bi380) (bi3903) D-lactate dehydrogenase (bi380) (bi3903) D-lactate dehydrogenase <td></td> <td></td> <td></td> <td></td> <td>(52001)</td> <td>2 oxogratarate reversible transport tha symport</td>					(52001)	2 oxogratarate reversible transport tha symport
B2 11.530 0.070 10 (b1852) Use of phosphate dehydrogenase 1 11.530 0.070 10 (b1243) D-lactate dehydrogenase 1 11.530 0.070 10 (b1243) D-lactate dehydrogenase 1 11.530 0.070 10 (b1380) NAD[P) transhydrogenase (L-serine) 1 11.530 0.070 10 (b3708) Tryptophanase (L-tryptophan) B2 11.530 0.070 10 (b2587) actaldehyde dehydrogenase (actv]lating) 1 (b43708) 10 (b2587) actaldehyde dehydrogenase (actv]lating) 1 (14875%) (-69.3%) (b1213) actaldehyde dehydrogenase (actv]lating) 1 0.0610 0.087 8 (b1380) OR (b2133) D-lactate dehydrogenase (actv]lating) 1 0.610 0.087 8 (b1602 AND b1603) NAD(P) transhydrogenase (actv]lating) 1 10.610 0.087 8 (b1603) NAD(P) transhydrogenase (actv]lating) 1 10.610 0.087 8 (b1602 AND b1603) NAD(P) transhydrogenase (actv]lating) 1 10.659%) (-62%) (b1602 AND b1603) D-lactate dehydrogenase (actv]lating) 1 10.650%		(1011070)	((b0870) OR (b2551)	D-alanine transaminase
B2 11.530 0.070 10 (b1380) OR (b2133) Datate dehydrogenase (b1380) OR (b2133) Datate dehydrogenase (b1380) OR (b2133) (b1380) OR (b2133) malic enzyme (NADP) (b1380) (b1602 AND b1603) malic enzyme (NADP) (b1602 AND b1603) NAD(P) transhydrogenase (periplasm) (14875%) (-69.3%) (b50351) (b1380) OR (b1241) acetaldehyde dehydrogenase (acetylating) (14875%) (-69.3%) (b5257) (14875%) (-69.3%) (b5257) (b1380) OR (b2133) Datate dehydrogenase (acetylating) (b2661) acetaldehyde dehydrogenase (b1380) (b1380) OR (b2133) Datate dehydrogenase (NADP) (b13659) (-62%) (b1002AND b1603) NAD(P) (13659%) (-62%) (b1002AND b1603) NAD(P) (13659%) (-62%) (b10301)OR (b2133) acetaldehyde dehydrogenase (b1360)OR (b2133) acetaldehyde dehydrogenase (b1402) Carcerductase (acetal) (1929%) (-62%) (b1002AND 1603) NAD(P) acetaldehyde dehydrogenase (b1360)OR(b2133) acetaldehyde dehydrogenase (b1402AND 1 acetaldehyde dehydrogenase <td></td> <td>(10410)0)</td> <td>(</td> <td></td> <td>(b0870) OR (b2551)</td> <td>D-alanine transaminase alanine transaminase</td>		(10410)0)	((b0870) OR (b2551)	D-alanine transaminase alanine transaminase
(b1842) (b1842) (ch1842) (b1842) (ch1842) (ch1842) (b1840) (ch1842) (ch1842) (b1840) (ch1842) (ch1842) (b1840) (ch1842) (ch1842) (b1840) (ch1842) (ch1842) (ch1842) (ch1843) (ch1842) (ch1842) (ch1843) (ch1842) (ch1842) (ch1843) (ch1842) (ch1842) (ch1843) (ch1842) (ch1842) (ch1842) (ch1842) (ch1852) (ch1852) (ch1852) (ch1852) (ch1852) (ch1852) (ch1852) (ch1852) (ch1852) (ch1852) (ch1852) (ch1852) (ch1850) (ch2133) (ch184) (ch263) malic enzyme (NADP) (ch264) (ch1850) (ch2133) (ch266) (ch263) malic enzyme (NADP) (ch263) (ch263) malic enzy		(10110)0)	((b0870) OR (b2551)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase
bi380) OR (b2133) D-lactate dehydrogenase bi380) OR (b2133) D-lactate dehydrogenase bi380) methylgivoal synthase (b4063) methylgivoal synthase (b4063) methylgivoal synthase (b4063) methylgivoal synthase (b4063) methylgivoal synthase (b40767) methylgivoal synthase (b4083) methylgivoal synthase (b4708) ND(P) transhydrogenase (nervine) B2 11.530 0.070 (14875%) (-69.3%) 10 (b3945) 2-oxoglutarate transport via symport (b3945) aldose reductase (acetol) Glycerol dehydrogenase (b1852) (b1852) glucose 6-phosphate dehydrogenase (b1852) malic enzyme (NADP) (b2661) succinate-semialdehyde dehydrogenase (b1852) malic enzyme (NADP) (b2663) malic enzyme (NADP) (b1602 AND b1603) ND(P) transhydrogenase (b1365%) (-62%) ((b331)OR(b2133)) (13659%) (-62%) ((b3845)) (b1602 AND b1603) ND(P) transhydrogenase (b1602 AND b1603) ND(P) transhydrogenase (b1852) glucose erductase (acetol) (J13659%) (-62%) <td></td> <td>(1011070)</td> <td>(, . ,</td> <td></td> <td>(b0870) OR (b2551)</td> <td>D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase</td>		(1011070)	(, . ,		(b0870) OR (b2551)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase
(b2463) malic enzyme (NÅDP) (b0963) methylgvoxal synthase (b4388) succinate-semialdehyde dehydrogenase (Deriplasm) (b4388) northylgvoxal synthase (b4388) succinate-semialdehyde dehydrogenase (periplasm) (b4601) northylgvoxal synthase (b4788) northylgvoxal synthase (b4788) northylgvoxal synthase (b4788) northylgvoxal synthase (b4787) (-69.3%) (b47878) (-69.3%) (b48758) (-69.3%) (b48758) (-69.3%) (b1852) acetaldehyde dehydrogenase (b1852) (b1852) (b1850) R(b1330) (b2661) succinate-semialdehyde dehydrogenase (b2661) succinate-semialdehyde dehydrogenase (b2661) succinate-semialdehyde dehydrogenase (b1360) (R02 AND b1603) NAD(P) (b13659%) (-62%) ((b1381)OR(b1241)) acetaldehyde dehydrogenase (acetylating) (b1602 AND b1603) NAD(P) (b1360)OR(b2133) aldose reductase (acetylating) (b1602 AND b1603) NAD(P) (b1602 AND b1603) NAD(P) (b1802 AND1603) D-lactate dehydrogenase (b1602 AND1603)		(1011070)	((()))		(b0870) OR (b2551) (b1852) (b1849)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAB transformylase.T
(b0963) methylglycxal synthase (b4388) phosphoserine phosphatase (L-serine) (b2661) succinate-semialdehyde dehydrogenase (NA (b3708) Tryptophanase (L-tryptophan) B2 11.530 0.070 10 (b43708) rpyptophanase (L-tryptophan) rpyptophanase (L-tryptophan) (14875%) (-69.3%) 10 (b0351) OR (b1241) actaldehyde schedydrogenase (actv1)ating) (14875%) (-69.3%) 10 (b2587) adose reductase (acto1) Glycerol dehydrogenase (acto1) (14875%) (-69.3%) (b1852) glucose 6-phosphate dehydrogenase (acty1)ating) (b1852) (b1850) OR (b2133) D-lactate dehydrogenase (acty1)ating) (b2661) succinate-semialdehyde ADP1 oxidoreductase (b2463) (b1602 AND b1603) NAD(P) transhydrogenase (acety1)ating) (b1602 AND b1603) (13659%) (-62%) ((b331)OR(b1241)) acetaldehyde dehydrogenase (acety1)ating) (b1602 AND b1603) malic enzyme (NADP) Glycerol dehydrogenase (acety1)ating) Glycerol dehydrogenase (acety1)ating) (13659%) (-62%) ((b380)OR(b2133))		(10110)0)	((b0870) OR (b2551) (b1852) (b1849) (b1380) OR (b2133)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase
(b4388) phosphoserine phosphatase (L-serine) (b2601) succinate-semialdehyde dehydrogenase (NA (b1602 AND b1603) B2 11.530 0.070 (14875%) (-69.3%) (b3945) acetaldehyde dehydrogenase (acetylating) (b3945) 2-coxoglutarate transport via symport (b1852) (b1852) (b1863) OR (b2133) (b1360) OR (b2133) (b13659%) (-62%) (b1002 AND b1603) NAD(P) transport via symport (b1360) OR (b2133) (b13659%) (-62%) (b1380) OR (b2133) (13659%) (-62%) (b1802 AND b1603) NAD(P) transhydrogenase (b1380) OR (b1213)) (13659%) (-62%) (b1800R(b2133)) acetaldehyde dehydrogenase (b1602 AND b1603) NAD(P) transhydrogenase (b1602 AND b1603) D-lactate dehydrogenase (b1602 AND b1603)		(10110)0)	((b0870) OR (b2551) (b1852) (b1849) (b1380) OR (b2133) (b2463)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP)
B2 11.530 0.070 10 (b301) NAD(P) transhydrogenase (L-tryptophan) B2 11.530 0.070 10 (b3708) Tryptophanase (L-tryptophan) B2 11.530 0.070 10 (b351) OR (b1241) acetaldehyd ehydrogenase (acetylating) (14875%) (-69.3%) 10 (b351) OR (b1241) acetaldehyd ehydrogenase (acetylating) (14875%) (-69.3%) 10 (b351) OR (b213) D-Lactaldehyde:NAD+1 -oxidoreductase (b1852) (b1852) (b1380) OR (b2133) D-Lactate dehydrogenase D-Lactate dehydrogenase (b2663) malic enzyme (NADP) to2661) succinate-semialdehyde dehydrogenase (b2663) (13659%) (-62%) (b10321)OR(b1241)) acetaldehyde dehydrogenase Cactoldehydrogenase (b1360)OR(b2133)) aldose reductase (acetol) D-Lactate dehydrogenase D-Lactate dehydrogenase (b1369)%) (-62%) (b1602AND1603) NAD(P) transhydrogenase D-Lactate dehydrogenase (b1602AND1603) (b1602AND1603) D-Lactate dehydrogenase D-Lactate dehydrogenase (b1602AND1603) </td <td></td> <td>(1011070)</td> <td>(</td> <td></td> <td>(b0870) OR (b2551) (b1852) (b1840) (b1380) OR (b2133) (b2463) (b50963)</td> <td>D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase</td>		(1011070)	((b0870) OR (b2551) (b1852) (b1840) (b1380) OR (b2133) (b2463) (b50963)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase
(b3708) Tryptophanase (L-tryptophan) B2 11.530 0.070 10 (b351) OR (b1241) acetaldehyde dehydrogenase (acetylating) (14875%) (-69.3%) (b2587) 2-oxoglutarate transport via symport (14875%) (-69.3%) (b3945) Glycerol dehydrogenase (acetol) (14875%) (-69.3%) (b1852) Glycerol dehydrogenase (b1852) D-Lactaldehyde:NAD+ 1-oxidoreductase (b1862) malic enzyme (NADP) (b2661) succinate-semialdehyde dehydrogenase (b2661) succinate-semialdehyde dehydrogenase (acetylating) (13659%) (-62%) (b3031)OR(b2133) (13659%) (-62%) (b1380)OR(b2133)) (b1602ANDb1603) D-lactate dehydrogenase (b1767) Glycerol dehydrogenase (b1763) D-lactate (b1602ANDb1603)) D-lactate dehydrogenase (b1767) Glycerol dehydrogenase (b1763) b-lactate (b1767) B-lactate dehydrogenase (b1767) Glycerol dehydrogenase (b1602ANDb1603)) NAD(P)<		(1011033)	((b0870) OR (b2551) (b1852) (b1849) (b1380) OR (b2133) (b2463) (b0963) (b4388)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine)
B2 11.530 0.070 10 (b0351) OR (b1241) acetaldehyde dehydrogenase (acetylating) (14875%) (-69.3%) (b2587) 2-oxog/utarate transport via symport (b3945) (b3945) 2-oxog/utarate transport via symport (b1852) (b1852) OLactaldehyde dehydrogenase (b1380) OR (b2133) D-Lactaldehyde dehydrogenase (b2661) succinate-semialdehyde dehydrogenase (b2663) succinate-semialdehyde dehydrogenase (b3659%) (-62%) (b1380)OR(b2133)) acetaldehyde dehydrogenase (b1360)A NAD(P) (b3659%) (-62%) (b1380)OR(b2133)) aldose reductase (acet)1 (b1360)A (b1602 AND b1603) (b1602 AND b1603) D-Lactate dehydrogenase (b1603) (b1602 AND b1241)) acetaldehyde dehydrogenase 0-Lactate (b1603) (b1602 AND b1603) (b1602AND1603)) D-Lactate dehydrogenase (b1602AND1603)) D-lactate dehydrogenase (b1602AND1603)) D-lactate dehydrogenase (b1025) (b2501) <td></td> <td>(1011070)</td> <td>(</td> <td></td> <td>(b0870) OR (b2551) (b1852) (b1840) (b2463) (b2463) (b0963) (b4388) (b2661) (b1602 AND b1603)</td> <td>D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transbydrogenase (neiphasm)</td>		(1011070)	((b0870) OR (b2551) (b1852) (b1840) (b2463) (b2463) (b0963) (b4388) (b2661) (b1602 AND b1603)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transbydrogenase (neiphasm)
(14875%) (-69.3%) (b2587) 2-oxoglutarate transport via symport aldose reductase (acctol) (b3945) (b3945) 2-oxoglutarate transport via symport aldose reductase (acctol) (b1852) (b1852) D-Lactaldehyde: NAD + 1-oxidoreductase (b1380) OR (b2133) (b1602 AND b1603) NAD(P) transhydrogenase (b13659%) (-62%) B3 10.610 0.087 8 ((b0351)OR(b1241)) (b13659%) (-62%) ((b1380)OR(b2133)) (b1602 AND b1603) NAD(P) transhydrogenase (b1380)OR(b2133)) D-Lactate dehydrogenase (acetylating) aldose reductase (acetol) (13659%) (-62%) ((b1380)OR(b2133)) D-Lactate dehydrogenase (b1602AND b1603) (b1602 AND b1603) D-Lactate dehydrogenase (b16030) D-Lactate dehydrogenase (AADP) (b1380)OR(b2133)) D-Lactate dehydrogenase (b1602AND b1603) D-Lactate dehydrogenase (b1602AND b1603) B4 9.284 0.093 5 ((b0356) OR (b121) OR (b1478)) alcohol dehydrogenase (chanol) glucose-6-phosphate isomerase polyphosphate kinase B4 9.284 0.093 5 (b0326) OR (b121) OR (b1478)) glucose-6-phosphate isomerase polyphosphate kinase		(1011033)	((b0870) OR (b2551) (b1852) (b1840) (b1380) OR (b2133) (b2463) (b4063) (b2661) (b2661) (b2662 AND b1603) (b3708)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine) succinate-semialdehydr dehydrogenase (NADP) NAD(P) transhydrogenase (Deriplasm) Tryptophanase (L-tryptophan)
(b3945) aldose reductase (acetol) Glycerol dehydrogenase D-Lactaldehyde:NAD+ 1-oxidoreductase (b1380) OR (b2133) D-Lactaldehyde:NAD+ 1-oxidoreductase (b2661) malic enzyme (NADP) (b2663) malic enzyme (NADP) (b13659%) (-62%) (b1360) OR (b2133) acetaldehyde dehydrogenase (b1360) OR (b2133) acetaldehyde dehydrogenase (acetylating) (13659%) (-62%) (b1380)OR(b2133)) acetaldehyde dehydrogenase (b1360)OR(b2133)) D-Lactate dehydrogenase (b1360)OR(b2133)) D-Lactate dehydrogenase (b1602ANDb1603) D-Lactate dehydrogenase (b1602ANDb1603) D-Lactate dehydrogenase (b1602ANDb1603)) D-Lactate dehydrogenase (b1602ANDb1603)) D-Lactate dehydrogenase (b19767) 6-phosphogluconolactonase (b1602ANDb1603)) NAD(P) transhydrogenase (11939%) (-59.5%) (b4025) (b2501) glucose-6-phosphate isomerase polyphosphate kinase polyphosphate kinase		11.530	0.070	10	(b0870) OR (b2551) (b1852) (b1849) (b2463) (b2463) (b4063) (b4083) (b4083) (b402 AND b1603) (b3708) (b3708)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (neiplasm) Tryptophanase (L-tryptophan) acetaldehyde dehydrogenase (acetylating)
$ \begin{array}{c ccccc} Giyceroi dehydrogenase \\ & & & & & & & & & & & & & & & & & & $	B ₂	11.530 (14875%)	0.070 (-69.3%)	10	(b0870) OR (b2551) (b1842) (b1340) OR (b2133) (b2463) (b4638) (b4388) (b2661) (b1602 AND b1603) (b3708) (b0351) OR (b1241) (b2587)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (periplasm) Tryptophanase (L-tryptophan) acetaldehyde dehydrogenase (acetylating) 2-oxoglutarate transport via symport
b1852) cb1852) cb1852) cb1852) cb1852) cb1852) cb1852) cb1852) cb1852) cb1852) cb1852) cb1852) cb1852) cb1852) cb1852) cb1203 cb1852) cb1852) cb1852) cb1203 cb1852) cb1852) cb1852) cb1203 cb2631) cb1203 cb1203 cb1207 cb2631) cb2631 cb1603 NAD(P) translydrogenase cb2732 cb2631) cb2631 cc264 cb1602 AND cb1602 cc264 cc264 cb1602 cb2631 cc264 cc264 cb2463) cb1602 cc264 cc264 cb2463) cb1602 cb1602 cc264 cb1602 cb1602 cc264 cc264 cb2463) cb1602 cc264 cc264 cb1602 cb1602 cc264 cc264 cb2463) cb1602 cc264 cc264 cb1602 cb1602 cc264 cc264 cb17 cb2463) cc264 cc264 cb1602 cc265 cc264 cc264 cb17 cc264 cc264 cc264 cb	B ₂	11.530 (14875%)	0.070 (-69.3%)	10	(b0870) OR (b2551) (b1852) (b1849) (b2463) (b2463) (b4683) (b4683) (b4684) (b4684) (b1602 AND b1603) (b3708) (b3708) (b3708) (b3541) OR (b1241) (b2587) (b3545)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (netylasm) Tryptophanase (L-tryptophan) acetaldehyde dehydrogenase (acetylating) 2-oxoglutarate transport via symport aldose reductase (acetol)
ib1380) OR (b2133) D-lactate dehydrogenase (b2463) mallc enzyme (NADP) (b2661) succinate-semialdehyde dehydrogenase (NA B3 10.610 0.087 8 (b0202 ND b1603) NAD(P) (13659%) (-62%) ((b0351)OR(b1241)) acetaldehyde dehydrogenase (acetylating) (13659%) (-62%) ((b1380)OR(b2133)) aldose reductase (acetol) (b1602 AND b1603) D-lactate dehydrogenase D-Lactate dehydrogenase (b1602 AND b1603) D-lactate dehydrogenase D-lactate dehydrogenase (b1603) (b1602ANDb1603)) D-lactate dehydrogenase (b1602ANDb1603)) NAD(P) resultater dehydrogenase (b1602ANDb1603)) NAD(P) resultater dehydrogenase (b10325) (b4025) NAD(P) (11939%) (-59.55%) (b4025) (b2501) polyphosphate kinase		11.530 (14875%)	0.070 (-69.3%)	10	(b0870) OR (b2551) (b1852) (b1849) (b2463) (b2463) (b4388) (b2661) (b1602 AND b1603) (b3708) (b3708) (b3708) (b357) (b3945)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformlyase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (netplasm) Tryptophanase (L-tryptophan) acetaldehyde dehydrogenase (acetylating) 2-oxoglutarate transport via symport aldose reductase (acetol) Glycerol dehydrogenase
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	B ₂	11.530 (14875%)	0.070 (-69.3%)	10	(b0870) OR (b2551) (b1842) (b1349) (b2463) (b2463) (b2661) (b2661) (b2681) (b2681) (b2687) (b3708) (b351) OR (b1241) (b2587) (b1852)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthas pluccuber implication (Lesrine) pluccuber implication (Lesrine) pluccuber implication (Lesrine) nuccuber implication (Lesrine) nucu
(b2661) succinate-semialdehyde dehydrogenase (NA NAD(P) transhydrogenase (NAD(P) transhydrogenase	B ₂	11.530 (14875%)	0.070 (-69.3%)	10	(b0870) OR (b2551) (b1852) (b1849) (b2463) (b2463) (b4063) (b4083) (b4083) (b402 AND b1603) (b3708) (b1602 AND b1603) (b3708) (b2587) (b395) (b1852) (b1852) (b1852) (b1850) OR (b2133)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformlyase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (netiplasm) Tryptophanase (L-tryptophan) acetaldehyde dehydrogenase (netylating) 2-oxoglutarate transport via symport aldose reductase (acetol) Glycerol dehydrogenase D-Lactaldehyde:NAD+ 1-oxidoreductase glucose 6-phosphate dehydrogenase
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	B ₂	11.530 (14875%)	0.070 (-69.3%)	10	(b0870) OR (b2551) (b1842) (b1840) (b2463) (b2463) (b4388) (b4388) (b4388) (b4388) (b4388) (b4388) (b4384) (b1602 AND b1603) (b3708) (b3587) (b2587) (b2587) (b2587) (b1852) (b1852) (b1852) (b1852) (b263) (b2463)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (nerjlasm) Tryptophanase (L-tryptophan) acetaldehyde dehydrogenase (acetylating) 2-oxoglutarate transport via symport aldose reductase (acetol) Glycerol dehydrogenase D-Lactaldehyde:NAD+ 1-oxidoreductase glucose 6-phosphate dehydrogenase D-lactate dehydrogenase malic enzyme (NADP)
D3 10.010 O.007 S (100331)(DR(01441)) accetainenyde dehydrogenase (accetylating) aldose reductase (acctol) (13659%) (-62%) (b13905) D-Lactate dehydrogenase (b1380)OR(b2133)) D-Lactate dehydrogenase (b1380)OR(b2133)) D-Lactate dehydrogenase (b160747) 6-phosphogluconolactonase (b1002ANDb1603)) NAD(P) transhydrogenase (11939%) (-59.55%) (b4025) (b2501) glucose-6-phosphate kinase	B ₂	11.530 (14875%)	0.070 (-69.3%)	10	(b0870) OR (b2551) (b1852) (b1849) (b2463) (b2463) (b4388) (b2661) (b1602 AND b1603) (b3708) (b1602 AND b1603) (b3708) (b26351) OR (b1241) (b2587) (b3945) (b3955) (b3	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase glucose 6-phosphate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatese (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (neiplasm) Tryptophanase (L-tryptophan) acetaldehyde dehydrogenase (netylating) 2-oxoglutarate transport via symport aldose reductase (acetol) Glycerol dehydrogenase D-Lactaldehyde:NADP 1-oxidoreductase glucose 6-phosphate dehydrogenase D-lactate dehydrogenase malic enzyme (NADP) succinate-semialdehyde dehydrogenase (NADP)
(1000000000000000000000000000000000000	B ₂	11.530 (14875%)	0.070 (-69.3%)	10	(b0870) OR (b2551) (b1852) (b1849) (b2463) (b2463) (b4388) (b2661) (b1602 AND b1603) (b3708) (b3708) (b3708) (b3557) (b3955) (b1852) (b1852) (b1852) (b1850) OR (b2133) (b2661) (b2662) (b2661) (b2662	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphates (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (netylating) acetaldehyde dehydrogenase (netylating) 2-oxoglutarate transport via symport aldose reductase (acetyla colour dehydrogenase D-Lactaldehyde:NAD+1-toxidoreductase glucose 6-phosphate dehydrogenase D-Lactaldehyde:NAD+1-toxidoreductase glucose 6-phosphate dehydrogenase D-Lactaldehyde:NAD+1-toxidoreductase glucose 6-phosphate dehydrogenase NAD(P) transhydrogenase NAD(P) transhydrogenase (NADP)
b D-Lactaldehyde:NAD+1-oxidoreductase (b1380)OR(b2133)) D-Lactaldehyde:NAD+1-oxidoreductase (b2463) malic enzyme (NADP) (b0767) 6-phosphogluconolactonase (b1602ANDb1603)) NAD(P) transhydrogenase (b1393%) (-59.55%) (b2501) glucose-6-phosphate kinase polyphosphate kinase polyphosphate kinase	B ₂	11.530 (14875%)	0.070 (-69.3%)	10	(b0870) OR (b2551) (b1852) (b1849) (b2463) (b2463) (b4083) (b4083) (b4083) (b4084) (b1602 AND b1603) (b3708) (b3510 OR (b2133) (b2463) (b2463) (b2464) (b1602 AND b1603) ((b0351)OR(b1241)) ((b3351)OR(b1241))	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) translydrogenase (certylatsm) Tryptophanase (L-tryptophan) acetaldehyde dehydrogenase (acetylating) 2-oxoglutarate transport via symport aldose roductase (acetyla Glycerol dehydrogenase D-Lactaldehyde: NAD+ 1-oxidoreductase glosse 6-phosphere dehydrogenase D-Lactaldehyde: NAD+ 1-oxidoreductase glosse 6-phosphere dehydrogenase malic enzyme (NADP) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (acetylating) addose roductase (acetylating) addose roductase (acetylating)
B4 9.284 0.093 5 (b1380)OR(b2133)) D-lactate dehydrogenase B4 9.284 0.093 5 (b1052ANDb1603)) B-brosphogluconolactonase (11939%) (-59.55%) (b4025) glucose-6-phosphate kinase (b2501) polyphosphate kinase polyphosphate kinase	B ₂	11.530 (14875%) 10.610 (13659%)	0.070 (-69.3%) 0.087 (-62%)	10 8	(b0870) OR (b2551) (b1840) (b1380) OR (b2133) (b2463) (b4063) (b4388) (b2661) (b1602 AND b1603) (b3708) (b102 AND b1603) (b2587) (b1380) OR (b1213) (b2463) (b2661) (b1602 AND b1603) (b2661) (b1602 AND b1603) ((b0351)OR(b1211)) ((b3945))	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine Aldolase glucose 6-phosphate dehydrogenase GAR transformlyase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (netylating) 2-oxoglutarate transport via symport aldose reductase (acetol) Glycerol dehydrogenase D-Lactaldehyde:NAD+ 1-oxidoreductase glucose 6-phosphate dehydrogenase D-Lactade dehydrogenase malic enzyme (NADP) NAD(P) transhydrogenase malic enzyme (NADP) acetaldehyde dehydrogenase (NADP) NAD(P) transhydrogenase (acetylating) addose reductase (acetylating) aldose reductase (acetylating) aldose reductase (acetylating)
(b2463) malic enzyme (NADP) (b0767) 6-phosphogluconolactonase (b1602ANDb1603)) NAD(P) transhydrogenase B4 9.284 0.003 5 (11939%) (-59.55%) (b4025) glucose-6-phosphate isomerase (b2501) polyphosphate kinase polyphosphate kinase	B2	11.530 (14875%) 10.610 (13659%)	0.070 (-69.3%) 0.087 (-62%)	10 8	(b0870) OR (b2551) (b1852) (b1849) (b2463) (b4384) (b4383) (b4384) (b4384) (b4384) (b4384) (b4384) (b4384) (b3945) (b1852) (b263) (b2641) (b1852) (b	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphase (Lesrine) phosphoserine phosphase (Lesrine) NAD(P) transhydrogenase (pariplasm) Tryptophanase (L-tryptophan) acetadehyde dehydrogenase (acetylating) 2-oxoglutante transport via symport aldose reductase (acetol) Glyceord dehydrogenase D-Lactaldehyde dehydrogenase D-Lactaldehyde dehydrogenase (acetylating) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase acetaldehyde dehydrogenase (acetylating) acetadehyde dehydrogenase (acetylating) aldose reductase (acetol) Glycerol dehydrogenase D-Lactaldehyde:NAD+ 1-oxidoreductase
(b0767) 6-phosphogluconolactonase B4 9.284 0.093 5 ((b1602ANDb1603)) NAD(P) transhydrogenase (11939%) (-59.55%) (b4025) alcohol dehydrogenase (ethanol) (b2501) polyphosphate kinase	B ₂	11.530 (14875%) 10.610 (13659%)	0.070 (-69.3%) 0.087 (-62%)	10	(b0870) OR (b2551) (b1840) (b1840) (b2463) (b2463) (b4388) (b2661) (b1602 AND b1603) (b2708) (b1022 AND b1603) (b2645) (b1852) (b1852) (b1852) (b1852) (b1860) OR (b2133) (b2661) (b2661) (b1800)OR(b2133)) ((b1880)OR(b2133))	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine Aldolase Stronoine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatese (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (nerjlasm) Tryptophanase (L-tryptophan) acetaldehyde dehydrogenase (netylating) 2-oxoglutarate transport via symport aldose reductase (acetol) Glycerol dehydrogenase malic enzyme (NADP) NAD(P) transhydrogenase malic enzyme (NADP) NAD(P) transhydrogenase acetaldehyde dehydrogenase (NADP) NAD(P) transhydrogenase D-lactate dehydrogenase D-Lactaldehyde intervenase D-Lactaldehyde intervenase D-Lactaldehydrogenase D-Lact
B4 9.284 0.093 5 ([b100ZAND10003)] NAD((7) transhydrogenase (11939%) (-59.55%) (b4025) alcohol dehydrogenase glucose-6-phosphate isomerase (b2501) (b4025) polyphosphate kinase polyphosphate kinase	B2	11.530 (14875%) 10.610 (13659%)	0.070 (-69.3%) 0.087 (-62%)	10	(b0870) OR (b2551) (b1852) (b1849) (b1380) OR (b2133) (b2463) (b4388) (b2661) (b1602 AND b1603) (b3708) (b1380) OR (b1241) (b2587) (b1380) OR (b2133) (b2661) (b1602 AND b1603) ((b1380) OR(b2133)) ((b1380) OR(b2133)) ((b1380) OR(b2133)) ((b1380) OR(b2133)) ((b1380) OR(b2133))	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphates (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (acetylating) 2-oxoglutarate transport via symport aldose reductase (acetol) Glycerol dehydrogenase pl-Lactaldehyde:NADP+ 1-oxidoreductase glucose 6-phosphate dehydrogenase malic enzyme (NADP) succinate-semialdehyde dehydrogenase malic enzyme (NADP) succinate-semialdehyde dehydrogenase [aldose reductase (acetol) Glycerol dehydrogenase malic enzyme (NADP) b-Lactaldehyde dehydrogenase [aldose reductase (acetol) Glycerol dehydrogenase acetaldehyde dehydrogenase malic enzyme (NADP) b-Lactate dehydrogenase D-Lactate dehydrogenase D-Lactate dehydrogenase Malco P) Horditorgenase D-Lactate dehydrogenase D-Lactate dehydrogenase Malco P) Malc(P) Clycerol dehydrogenase D-Lactate dehydrogenase D-Lactate dehydrogenase Malco P) D-Lactate D-D) D-Lactate D-D) D-Lactate D-D) D-Lactate D-D) D-D) D-D) D-D) D-D) D-D) D-Lactate D-D) D-D
(11939%) (-59.55%) (bd025) (bd	B ₂	11.530 (14875%) 10.610 (13659%)	0.070 (-69.3%) 0.087 (-62%)	10	(b0870) OR (b2551) (b1852) (b1849) (b1380) OR (b2133) (b2463) (b4638) (b4638) (b4638) (b4602 AND b1603) (b2661) (b1852) (b1852) (b1852) (b1852) (b1852) (b1862 AND b1603) (b2661) (b6023 ND b1603) ((b43945)) ((b1380) OR (b2133)) (b2463) (b4363) (b4363) (b40767) MD1 1000)	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine Aldolase glucose 6-phosphate dehydrogenase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatese (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (periplasm) Tryptophanase (L-tryptophan) acetaldehyde dehydrogenase (acetylating) 2-oxoglutarate transport via symport aldose reductase (acetol) Glycerol dehydrogenase malic enzyme (NADP) -lactate dehydrogenase malic enzyme (NADP) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase acetaldehyde dehydrogenase (acetylating) aldose reductase (acetol) Glycerol dehydrogenase (acetylating) aldose reductase (acetol) Glycerol dehydrogenase D-lactatel dehydrogenase D-lactatel dehydrogenase D-lactatel dehydrogenase malic enzyme (NADP) totalored dehydrogenase malic enzyme (NADP) Solarete dehydrogenase malic enzyme (NADP)
(b2501) polyphosphate kinase polyphosphate kinase	B ₂	11.530 (14875%) 10.610 (13659%)	0.070 (-69.3%) 0.087 (-62%)	10 8	(b0870) OR (b2551) (b1852) (b1849) (b1380) OR (b2133) (b2463) (b4388) (b2661) (b1602 AND b1603) (b3788) (b1602 AND b1603) (b2587) (b1852) (b1852) (b1852) (b1852) (b1860 OR (b2133) (b2661) (b1602 AND b1603) (b1850) (b1380)OR(b2133)) (b2463) (b1602AND b1603) ((b1380)OR(b2133)) (b2463) (b1602AND b1603)) ((b1380)OR(b2133)) (b2463) (b1602AND b1603)) ((b1380)OR(b2133)) (b2463) (b1602AND b1603)) ((b1380)OR(b2133)) (b2463) (b1602AND b1603)) ((b1380)OR(b2133)) (b2463) (b0767) ((b1602AND b1603)) ((b1380)OR(b2133)) (b2463) (b0767) ((b1602AND b1603)) ((b1800)OR(b2133)) (b2463) (b0767) (b0767) (b076	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine Aldolase glucose 6-phosphate dehydrogenase GAR transformlyase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (netylating) 2-oxoglutarate transport via symport aldose reductase (acetol) Glycerol dehydrogenase malic enzyme (NADP) -D-Lactaldehyde dehydrogenase malic enzyme (NADP) NAD(P) transhydrogenase malic enzyme (NADP) acetaldehyde dehydrogenase malic enzyme (NADP) NAD(P) transhydrogenase D-Lactaldehyde:NAD+ 1-oxidoreductase D-Lactaldehyde:NAD+ 1-oxidoreductase D-Lactaldehyde:NAD+ 1-oxidoreductase D-Lactaldehyde:NAD+ 1-oxidoreductase D-Lactaldehyde:NAD+ 1-oxidoreductase D-Lactaldehyde:NAD+ 1-oxidoreductase D-Lactaldehyde:NADP + 1-oxidoreductase malic enzyme (NADP) 0-lactase (acetol) Glycerol dehydrogenase MAD(P) transhydrogenase malic enzyme (NADP) (s-phosphogluconalactonase NAD(P) transhydrogenase (s-phosphogluconalactonase NAD(P) transhydrogenase (s-phosphogluconalactonase (s-phosphogluconalactonase (s-phosphogluconalactonase (s-pho
polyphosphate kinase	B ₂ B ₃ B ₄	11.530 (14875%) 10.610 (13659%)	0.070 (-69.3%) 0.087 (-62%) (-62%)	10 8 5	(b0870) OR (b2551) (b1852) (b1849) (b1380) OR (b2133) (b2463) (b4083) (b4083) (b4083) (b1602 AND b1603) (b1602 AND b1603) (b1852	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatese (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (periplasm) Tryptophanase (L-tryptophan) acetaldehyde dehydrogenase (acetylating) 2-oxoglutarate transport via symport aldose roductase (acetol) Glycerol dehydrogenase 0-Lactaldehyde: NAD+ 1-oxidoreductase glucose 6-phosphate dehydrogenase D-lactate dehydrogenase (acetylating) acetaldehyde: NAD+ 1-oxidoreductase glucose 6-phosphate dehydrogenase NAD(P) transhydrogenase (acetylating) aldose reductase (acetol) Glycerol dehydrogenase D-Lactaldehyde: NADP) -D-Lactatedhydrogenase D-Lactate dehydrogenase D-Lactate dehydrogenase D-Lactate dehydrogenase D-Lactate dehydrogenase MAD(P) (E-phosphogluconolactonase NAD(P) (E-phosphogluconolactonase (E-E-E-E-E-E-E-E-E-E-E-E-E-E-E-E-E-E-E-
	- B ₂	11.530 (14875%) 10.610 (13659%) 9.284 (11939%)	0.070 (-69.3%) 0.087 (-62%) 0.093 (-59.55%)	10 8 5	(b0870) OR (b2551) (b1840) (b1840) (b2463) (b2463) (b4388) (b2661) (b1602 AND b1603) (b2587) (b1852) (b1852) (b1852) (b1852) (b1852) (b1860 OR (b2133) (b2661) (b1602 AND b1603) ((b0351)OR(b1241)) ((b3945)) ((b1380)OR(b2133)) (b2463) (b1850) ((b1380)OR(b2133)) (b2463) (b1850) ((b1380)OR(b2133)) (b2463) (b0767) ((b1602ANDb1603)) ((b0356) OR (b1241) OR (b1478)) (b4025)	D-alanine transaminase lanine transaminase L-allo-Threonine Aldolase Threonine Aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatese (L-serine) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase (nerjlasm) Tryptophanase (L-tryptophan) acetaldehyde dehydrogenase (netylating) 2-oxoglutarate transport via symport aldose reductase (acetol) Glycerol dehydrogenase D-lactate dehydrogenase malic enzyme (NADP) NAD(P) transhydrogenase acetaldehyde dehydrogenase malic enzyme (NADP) Succinate-semialdehyde dehydrogenase D-lactate dehydrogenase D-Lactaldehyde iNADP 1-oxidoreductase D-Lactaldehyde iNADP1 acetaldehyde dehydrogenase D-Lactaldehyde:NAD+ 1-oxidoreductase D-Lactaldehyde:NAD+ 1-oxidoreductase D-Lactaldehyde:NAD+ 1-oxidoreductase D-Lactaldehydrogenase malic enzyme (NADP) 6-phosphogluconlactonase NAD(P) transhydrogenase (shanol) glucose-6-phosphate isomerase polyphosphate kinase
*We report the protein 1) "Nuo" associated to the gene set: (b2276 AND b2277 AND b2278 AND b2279 AND b2280 AND b2280	B2 B3 B4	11.530 (14875%) 10.610 (13659%) 9.284 (11939%)	0.070 (-69.3%) 0.087 (-62%) 0.093 (-59.55%)	10 8 5	(b0870) OR (b2551) (b1852) (b1849) (b1380) OR (b2133) (b2463) (b4083) (b4083) (b4093) (b4093) (b4093) (b4093) (b4093) (b3945) (b1852) (b1852) (b1852) (b1853) OR (b2133) (b2463) (b2463) (b2463) (b3945)) ((b1835)OR(b2133)) (b2463) (b2	D-alanine transaminase alanine transaminase L-allo-Threonine Aldolase Threonine aldolase glucose 6-phosphate dehydrogenase GAR transformylase-T D-lactate dehydrogenase malic enzyme (NADP) methylglyoxal synthase phosphoserine phosphatase (L-serine) phosphoserine phosphatase (L-serine) stranstyre (NADP) NAD(P) translydrogenase (nertylating) actaldhydre dehydrogenase (nertylating) 2-dometric dehydrogenase D-Lactaldehydre (Artyptophan) actaldhydre (Artyptophan) 2-dometric dehydrogenase D-Lactaldehydre,NAD+ 1-oxidoreductase glucose 6-phosphate dehydrogenase (nettyl) succinate-semialdehyde dehydrogenase (nettyl) succinate-semialdehyde dehydrogenase (NADP) NAD(P) transhydrogenase D-Lactaldehyde:NAD+ 1-oxidoreductase D-Lactate dehydrogenase D-Lactate D-Dopenate (Inase) D-Lactate D-Dopenate (Inase) D-Dopenate

AND 52280, AND 52280 AND 52280 AND 52280 AND 52280 AND 52280, AND 52280, AND 52282 AND 52483 AND 52483 AND 52484 AND 52485 AND 52480 AND 52480 AND 52280 AND 52290 AND 52720 AND

In order to study the favourable environmental conditions, i.e. nutrients for *E. coli*, we performed the simultaneous optimisation of acetate, succinate and biomass on the complete network, i.e. without knockouts. We consider the anaerobic and aerobic condition (O₂ uptake rate = $10 \ mmolh^{-1}gDW^{-1}$) by keeping fixed the glucose uptake rate to $10 \ mmolh^{-1}gDW^{-1}$. We use the Non-Dominated Sorting Genetic Algorithm II [13] to perform optimisation by exploring the continuous space of exchange fluxes. The algorithm implements the *Simulated Binary Crossover* operator for crossover and the *polynomial mutation*. In our analysis, the decision variable vector is the lower bound vector of the flux values that constitute the 297 exchange fluxes (glucose and oxygen are kept constant) in the FBA model of *E. coli*. The decision variables are real values from 0 to -100 (0 when the uptake is not allowed, -100 when the potential uptake rate is 100 mmol gDW⁻¹ h⁻¹). The algorithm parameters are the population size (set as 100 individuals) and the generation number (set at 500).

Our method reaches the maximum value of acetate $(+100 \text{ mmol gDW}^{-1} \text{ h}^{-1})$, and highlights conflictive behaviour of biomass and succinate (see their maximisation in the Pareto fronts of Figure 6). In anaerobic condition, we found 100 mmolh⁻¹ gDW⁻¹ h⁻¹ of acetate, 42.918 mmolh⁻¹ gDW⁻¹ of succinate and 3.6204 h⁻¹ of biomass (the trade-off). In this condition, we individuated a significant increment in the L-Aspartate, Citrate, Lactose, Fumarate and Malate uptake rates. Instead, in aerobic condition, we found 100 mmolh⁻¹ gDW⁻¹ h⁻¹ of acetate, 21.889 mmolh⁻¹ gDW⁻¹ of succinate and 4.16 h⁻¹ of biomass and a significant increment in the L-Asparagine, 1, 4-alpha-D-glucan, Fe(III)dicitrate, 2-Oxoglutarate uptake rates. In our analysis, we perturbed simultaneously almost



Fig. 5. Pareto fronts obtained by optimising the acetate production $[mmolh^{-1} \text{ gDW}^{-1}]$ (A), succinate production (B) and the biomass formation $[h^{-1}]$ using GDMO algorithm in four organisms models: *E. coli*, *M. barkeri*, *G. sulfurreducens* and *Y. Pestis*. For *Y. Pestis* we consider two biomass compositions: at 24-28 °C and 37 °C. The significance of these two temperatures stems from the two types of hosts that *Y. Pestis* infects in the natural environment, namely insect vectors at ambient temperature and mammalian hosts with regulated body temperatures of about 37°C. In *M. barkeri*, *G. sulfurreducens* and *Y. Pestis*, the yield of acetate and biomass is larger than *E. coli* due to the lower number of reactions in the metabolic reconstructions.

all the exchange fluxes, but it is possible to select a smaller set of nutrients to study according to experimental requirement.

Sensitivity analysis results are shown in Figure 2, revealing that only 70 out of 299 are influent in the output of the model, i.e., the remaining do not change significantly the metabolic network. In particular, *Chloride*, *Zinc*, Co2+, *L*-*Glutamate exchanges* are the most sensitive (the complete list is reported in Figure 2).



Fig. 6. Feasible regions for acetate production, succinate production (y axis) and biomass formation (x axis). We consider the wild-type bacteria (i.e. knockout zero) and perform the optimisation in aerobic ($O2 = 10 \text{ mmolh}^{-1} \text{ gDW}^{-1}$, in blue) and anaerobic (black) conditions on a basis of 10 mmolh⁻¹ gDW⁻¹ glucose fed to identify favourable nutrients. In both conditions, the algorithm reaches the maximum production of acetate (100 mmolh⁻¹ gDW⁻¹).

4 Conclusions

This paper highlights that the Pareto front has a close link with the biotechnology productivity. For the biosynthesis, Pareto optimality is important to obtain not only a wide range of Pareto optimal solutions, but also the *best trade-off design*. Pareto front provides not merely the visualisation of the optimisation process, but also significant information in metabolic design automation. For instance, the size of non-dominated solutions, the first derivative and the area under the Pareto curve could play a key role for the best design within the same organism or between different organisms. Remarkably, the reduced size of the Pareto front could indicate the incompleteness of the model in terms of the number of reactions modelled; in this case, the Pareto optimality could be thought of as a parameter describing the improvement of a model for a bacterium with respect to a previous model for the same bacterium.

Exploratory analysis and comparative metabolic models suggest that the area underlying the Pareto provides an estimate of the number of intermediates which may be exploited for biotechnological purposes (optimisation of an additional objective) or to build synthetic pathways (synthetic biology). Given two bacteria or two conditions for the same bacterium, a larger area under the Pareto front probably represents the best conditions for adding or optimising pathways leading to new biotechnological products. The slope of the Pareto front reflects the progressive lack of pathways able to sustain the production of one component when we are optimising the metabolism to maximise the other. The anaerobic Pareto front has also many more jumps (quick decreases) than the aerobic one. Jumps mark the sudden loss of pathways due to the critical unavailability of an enzymatic step. In other words they correspond to sudden decreases in the availability of entire pathways and subnetworks when a crucial hub is eliminated (e.g., the Krebs cycle). The region of the Pareto front nearby a jump suggests that slight changes of conditions, or a handful of genetic mutations, may result in a large change in the amount of product. Hence, the first derivative, and in particular its discontinuity, indicates the preferable conditions for the metabolites production as highlighted in the Figure 3-C-D regarding succinate and biomass optimisation. In fact, Pareto front in aerobic condition presents a wide jump, confirming that anaerobic condition is favourable for succinate fermentation as given in literature, while in aerobic condition succinate is used as intermediate to produce energy and is totally consumed. GDMO scales effectively as the size of the metabolic system and the number of genetic manipulations increase. Moreover, our results show that the multi-objective approach is very suitable for the genetic design strategies (GDS) discovering. We believe that the algorithm could be further extended and tuned to specific cases.

In the framework we propose in our work, the robustness analysis allows currently to discriminate the strains based on GR or R value: the higher these values, the greater the possibility that bacteria, reproduced in laboratory, maintain the desired performance. In future works, the local robustness analysis and other statistical connected analysis will enable us to reach a better understanding of the metabolic network fragility and this could help the GDMO algorithm to find more robust strains.

References

- Alper, H., Miyaoku, K., Stephanopoulos, G.: Construction of lycopeneoverproducing E. coli strains by combining systematic and combinatorial gene knockout targets. Nature Biotechnology 23(5), 612–616 (2005)
- Jarboe, L.R., Zhang, X., Wang, X., Moore, J.C., Shanmugam, K.T., Ingram, L.O.: Metabolic engineering for production of biorenewable fuels and chemicals: Contributions of synthetic biology. Journal of Biomedicine and Biotechnology (2010)
- Atsumi, S., Wu, T.Y., Eckl, E.M., Hawkins, S.D., Buelter, T., Liao, J.C.: Engineering the isobutanol biosynthetic pathway in Escherichia coli by comparison of three aldehyde reductase/alcohol dehydrogenase genes.. Applied Microbiology and Biotechnology 85(3), 651–657 (2010)
- Orth, J.D., Thiele, I., Palsson, B.Ø.: What is flux balance analysis? Nature Biotechnology 28(3), 245–248 (2010)
- 5. Patil, K.R., Rocha, I., Förster, J., Nielsen, J.: Evolutionary programming as a platform for in silico metabolic engineering. BMC Bioinformatics 6(1), 308 (2005)

- Rocha, M., Maia, P., Mendes, R., Pinto, J.P., Ferreira, E.C., Nielsen, J., Patil, K.R., Rocha, I.: Natural computation meta-heuristics for the in silico optimization of microbial strains. BMC Bioinformatics 9(1), 499 (2008)
- Lun, S.D., Rockwell, G., Guido, N.J., Baym, M., Kelner, J.A., Berger, B., Galagan, J.E., Church, G.M.: Large-scale identification of genetic design strategies using local search. Mol. Syst. Biol. 5(296) (2009)
- Burgard, A.P., Pharkya, P., Maranas, C.D.: Optknock: a bilevel programming framework for identifying gene knockout strategies for microbial strain optimization. Biotechnology and Bioengineering 84(6), 647–657 (2003)
- Pharkya, P., Maranas, C.: An optimization framework for identifying reaction activation/inhibition or elimination candidates for overproduction in microbial systems. Metabolic Engineering 8(1), 1–13 (2006)
- Sun, J., Sayyar, B., Butler, J.E., Pharkya, P., Fahland, T.R., Famili, I., Schilling, C.H., Lovley, D.R., Mahadevan, R.: Genome-scale constraint-based modeling of *Geobacter metallireducens*. BMC Systems Biology 3(1), 15+ (2009)
- Feist, A.M., Scholten, J.C.M., Palsson, B.Ø., Brockman, F.J., Ideker, T.: Modeling methanogenesis with a genome-scale metabolic reconstruction of Methanosarcina barkeri. Mol. Syst. Biol. 2 (January 2006)
- Charusanti, P., Chauhan, S., McAteer, K., Lerman, J.A., Hyduke, D.R., Motin, V.L., Ansong, C., Adkins, J.N., Palsoon, B.Ø.: An experimentally-supported genome-scale metabolic network reconstruction for *Yersinia pestis* co92
- Deb, K., Pratap, A., Agarwal, S., Meyarivan, T.: A fast and elitist multiobjective genetic algorithm: NSGA-II. IEEE Transactions on Evolutionary Computation 6(2), 182–197 (2002)
- Sendin, J.O., Alonso, A., Banga, J.: Multi-objective optimization of biological networks for prediction of intracellular fluxes. In: Corchado, J., De Paz, J., Rocha, M., Rocha, M., Fernández Riverola, F. (eds.) 2nd International Workshop on Practical Applications of Computational Biology and Bioinformatics (IWPACBB 2008). AISC, vol. 49, pp. 197–205. Springer, Heidelberg (2009)
- Schuetz, R., Zamboni, N., Zampieri, M., Heinemann, M., Sauer, U.: Multidimensional optimality of microbial metabolism. Science 336(6081), 601–604 (2012)
- Xu, M., Bhat, S., Smith, R., Stephens, G., Sadhukhan, J.: Multi-objective optimisation of metabolic productivity and thermodynamic performance. Computers & Chemical Engineering 33(9), 1438–1450 (2009)
- Laumanns, M., Thiele, L., Deb, K., Zitzler, E.: Combining convergence and diversity in evolutionary multiobjective optimization. Evol. Comput. 10(3), 263–282 (2002)
- Stracquadanio, G., Umeton, R., Papini, A., Liò, P., Nicosia, G.: Analysis and optimization of c3 photosynthetic carbon metabolism. In: Rigoutsos, I., Floudas, C.A. (eds.) Proceedings of 10th IEEE International Conference on Bioinformatics and Bioengineering (IEEE BIBE), Philadelphia, PA, USA, May 31-June 3, pp. 44–51. IEEE Computer Society (2010)
- Umeton, R., Stracquadanio, G., Papini, A., Costanza, J., Lio, P., Nicosia, G.: Identification of sensitive enzymes in the photosynthetic carbon metabolism. Advances in Experimental Medicine and Biology 736, 441–459 (2012)
- Zhang, H.X., Goutsias, J.: A comparison of approximation techniques for variancebased sensitivity analysis of biochemical reaction systems. BMC Bioinformatics 11(246) (2010)
- Rodriguez-Fernandez, M., Banga, J.R.: Senssb: a software toolbox for the development and sensitivity analysis of systems biology models. Bioinformatics 26(13), 1675–1676 (2010)

- Morris, M.D.: Factorial sampling plans for preliminary computational experiments. Technometrics 33(2), 161–175 (1991)
- Callaway, D.S., Newman, M.E.J., Strogatz, S.H., Watts, D.J.: Network robustness and fragility: Percolation on random graphs. Physical Review Letters 85, 5468–5471 (2000)
- Shinar, G., Alon, U., Feinberg, M.: Sensitivity and robustness in chemical reaction networks. SIAM Journal of Applied Mathematics 69(4), 977–998 (2009)
- Hafner, M., Koeppl, H., Hasler, M., Wagner, A.: Glocal robustness analysis and model discrimination for circadian oscillators. PLoS Comput. Biol. 5(10) (2009)
- Donaldson, R., Gilbert, D.: A Model Checking Approach to the Parameter Estimation of Biochemical Pathways. In: Heiner, M., Uhrmacher, A.M. (eds.) CMSB 2008. LNCS (LNBI), vol. 5307, pp. 269–287. Springer, Heidelberg (2008)
- Lodhi, H., Gilbert, D.: Bootstrapping Parameter Estimation in Dynamic Systems. In: Elomaa, T., Hollmén, J., Mannila, H. (eds.) DS 2011. LNCS, vol. 6926, pp. 194–208. Springer, Heidelberg (2011)
- Umeton, R., Stracquadanio, G., Sorathiya, A., Papini, A., Lio, P., Nicosia, G.: Design of robust metabolic pathways. In: Design Automation Conference (DAC), 2011 48th ACM/EDAC/IEEE, pp. 747–752 (June 2011)
- Nicosia, G., Rinaudo, S., Sciacca, E.: An evolutionary algorithm-based approach to robust analog circuit design using constrained multi-objective optimization. Knowledge-Based Systems 21(3), 175 (2008), The 27th SGAI International Conference on Artificial Intelligence
- Feist, A.M., Henry, C.S., Reed, J.L., Krummenacker, M., Joyce, A.R., Karp, P.D., Broadbelt, L.J., Hatzimanikatis, V., Palsson, B.Ø.: A genome-scale metabolic reconstruction for escherichia coli k-12 mg1655 that accounts for 1260 orfs and thermodynamic information. Mol. Syst. Biol. 3(121), 291–301 (2007)